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7IV. Abstract
The construction of adenovirus vectors for cloning and foreign gene expression requires
packaging cell lines that can complement missing viral functions caused by sequence deletions
and/or replacement with foreign DNA sequences. In this study, packaging cell lines were
designed to provide in trans the missing bovine adenovirus functions, so that recombinant
viruses could be generated.
Fetal bovine kidney and lUng cells, acquired at the trimester term from a pregnant cow,
were tranfected with both digested wild type BAV2 genomic DNA and pCMV-EI. The plasmid
pCMV-EI was specifically constructed to express El of BAV2 under the control of the
cytomegalovirus enhancer/promoter (CMV). Selection for "true" transformants by continuous
passaging showed no success in isolating immortalised cells, since the cells underwent crisis
resulting in complete cell death. Moreover, selection for G418 resistance, using the same cells,
also did not result in the isolation of an immortalised cell line and the same culture-collapse
event was observed.
The lack of success in establishing an immortalised cell line from fetal tissue prompted us
to transfect a pre-established cell line. We began by transfecting MDBK (Mardin-Dardy bovine
kidney) cells with pCMV-El-neo, which contain the bacterial selectable marker neo gene. A
series of MDBK-derived cell lines, that constitutively express bovine adenoviral (BAV) early
region 1 (El), were then isolated. Cells selected for resistance to the drug G418 were isolated
collectively for full characterisation to assess their suitability as packaging cell lines. Individual
colonies were isolated by limiting dilution and further tested for El expression and efficiency of
DNA uptake. Two cell lines, L-23 and L-24, out of 48 generated foci tested positive for £1
expression using Northern Blot analysis. DNA uptake studies, using both lipofectamine and
calcium phosphate methods, were performed to compare these cells, their parental MDBK cells,
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and the unrelated human 293 cells as a benchmark. The results revealed that the new MDBK-
derived clones were no more efficient than MDBK cells in the transient expression of transfected
DNA and that they were inferior to 293 cells, when using lacZ as the reporter gene.
In view of the inherently poor transfection efficiency of MDBK cells and their
derivatives, a number of other bovine cells were investigated for their potential as packaging
cells. The cell line CCL40 was chosen for its high efficiency in DNA uptake and subsequently
transfected with the plasmid vector pCMV El-neo. By selection with the drug G418, two cell
lines were isolated, ProCell 1 and ProCell 2. These cell lines were tested for El expression,
permissivity to BAV2 and DNA uptake efficiency, revealing a DNA uptake efficiency of 37 % ,
comparable to that of CCL40.
Attempts to rescue BAV2 mutants carrying the lacZ gene in place of £1 or £3 were
carried out by co-transfecting wild type viral DNA with either the plasmid pdlElE-Z (which
contains BAV2 sequences from 0% to 40.4% with the lacZ gene in place of the £1 region from
1.1% to 8.25%) or with the plasmid pdlE3-5-Z (which contains BAV2 sequences from 64.8% to
100% with the lacZ gene in place of the E3 region from 75.8% to 81.4%). These co-
transfections did not result in the generation of a viral mutant. The lack of mutant generation
was thought to be caused by the relative inefficiency of DNA uptake.
Consequently, cosBAV2, a cosmid vector carrying the BAV2 genome, was modified to
carry the neo reporter gene in place of the £3 region from 75.8% to 81.4%. The use of a single
cosmid vector earring the whole genome would eliminate the need for homologous
recombination in order to generate a viral vector. Unfortunately, the transfection of cosBAV2-
neo also did not result in the generation of a viral mutant. This may have been caused by the size
of the £3 deletion, where excess sequences that are essential to the virus' survival might have
been deleted. As an extension to this study, the spontaneous E3 deletion, accidently discovered
in our viral stock, could be used as site of foreign gene insertion.
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VI. Literature Review
A. Aden0 v"uses
Adenovirus (Ad) was first isolated by two independent groups of investigators, Rowe and
co-workers in 1953 and Hilleman and Werner in 1954 (reviewed in Fields et al., 1996). Both
groups observed the spontaneous degeneration of primary cell cultures established from human
adenoid tissue that was removed by tonsillectomy from military recruits with febrile illness. This
pathogenic element was shown to be a virus that was not previously identified and it was given
several names at first: adenoid degeneration, respiratory illness, adenoidal-pharyngeal-
conjunctival and acute respiratory disease agents. Epidemiological studies confirmed that the
agents were the cause of acute febrile respiratory syndromes and in 1956 they were named
adenoviruses (reviewed in Fields et al., 1996).
In 1962, Trentin and co-workers made a shocking discovery. They showed that newborn
hamsters developed tumours upon inoculation with the human adenovirus type 12 (Ad12)
(Trentin et al., 1962). However, since then, all studies have failed to detect the presence of
adenoviral DNA in human tumours or to link adenoviruses to human malignant diseases.
Currently there are over 100 members of the Ad group which have been identified and
isolated from a variety of species. Although interest in these viruses originally centered on their
properties as tumour viruses, an important discovery was made revealing mRNA splicing and the
presence of introns (Berk et al., 1977; and Chow et al., 1977). The interest in studying Ad
pathogenicity continued and with the development of recombinant DNA techniques,
adenoviruses became of great interest as viral vectors for gene therapy and viral vaccines.
11
1. Epidemiology
Adenoviruses are widespread in nature. They infect birds, mammals and humans (Table
1). Most of the infections are subclinical. Although these viruses have a higher tendency to
;'
infect the respiratory and gastrointestinal tract, they were also shown to infect the bladder, the
eyes, and the central nervous system (very rare) (reviewed in Fields et aI., 1996).
Table 1: Diseases caused by human Ads.
Groups at risk and diseases caused by human Ads (compiled from Ford et a/., 1993;
Grimwood et a/., 1995; and Hitt et a/., 1997)
2. Classification
Adenoviruses are non-enveloped double-stranded DNA VIruses. The family
Adenoviridae is divided into the genera Mastadenovirus and Aviadenovirus (reviewed in Fields
et al., 1996). The Mastadenovirus genus includes human, simian, bovine, equine, porcine, ovine,
canine, caprine, murine, and tree shrew viruses, while the Aviadenovirus genus includes five
groups of viruses that infect birds (reviewed in Fields et al., 1996). Thus far, 49 human Ad
serotypes have been classified into six subgroups according to their haemagglutination properties
and their resistance to neutralisation by antiserum to known Ads (Hierholzer et al., 1988).
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Table 2: Ad Classification.
Ad serotypes classified into subgroups based on oncogenicity potential and
hemagglutination (Wadell, 1994)
D 8, 9, 10, 13,
15, 17, 19,
20, 22-30, 32,
33, 36-39,
42-47
None +/- + 57-61
A recent study by Dan et al. (1998) revealed the possible need for a third genus in the
Adenoviridae family (Figure 1). The proposed name of the new genus was Atadenovirus (A-T
rich adenoviruses). This members of the new proposed genus are BAV4 to 8, EDS (Duck Ad1)
and OAV287 (Ovine Ad isolate number 287). The reason for this proposition is that these
members behave differently from the rest of the Mastadenovirus genus and that there is high
homology of DNA sequence between them. These viruses have 60% A-T rich coding regions,
compared to the 42% to 52 % in other Mastadenovirus members. They show some degree of
heat resistance, provoke inclusion bodies that are structurally different from the inclusion bodies
caused by other mastadenoviruses and fail complement fixation that is cornmon to all members
of Mastadenovirus. Members of the proposed Atadenovirus genus can be only propagated in
testicular or thyroid cell cultures, however other members of the Mastadenovirus genus can be
propagated in kidney and testicular cell cultures. Also, protease and hexon sequences were
aligned with sequences from other viruses in the Mastadenovirus genus to further show a
distinctive cluster containing BAV4, OAV287 and EDS.
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Adenoviridae
!
Avian
Subgroup II
BAV 4-8
Aviadenovirus Atadenovirus (?)
I BAV 4-8
+ EDS
OAV287iBovine
I
~
Subgroup I
BAV 1-3,9,10
Mastadenovirus
I
~
Human
Canine
Ovine
Equine
Porcine
Murine
Simian
Tree Shrew
Figure 1: Ad classification.
The figure shows the two genera previously assigned, Mastadenovirus and
Aviadenovirus, plus the new proposed genus, Atadenovirus , based on a study by Dan
etal. (1998).
3. Structure
Adenoviruses are non-enveloped viruses, icosahedral in shape with a diameter of 70-100
run (Home et al., 1959). The viral particles contain 13% DNA and 87% protein by weight
(Ishibashi et al., 1974).
a) Capsid and Core Protein Organisation
The protein capsid of the virus is composed of252 capsomeres which include 240 hexons
and twelve pentons (Figure 2). Pentons contain a base (part of the capsid) and a projecting fibre
protein. The outer capsid is made of seven polypeptides (II, ID, IDa, IV, VI, Vill, IX), while the
core structure is made of 4 proteins (V, Vll, X, and TP) and the DNA genome ( reviewed in
Fields et al., 1996)
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Figure 2: Structure of Ads.
(left) A schematic representation of an Ad showing the fibre protein projections and the
viral capsid. The capsid consists of the hexon and penton proteins. Inside the capsid,
the figure shows the coiled genome with the terminal proteins bound to its 5' ends
(Stewart et al., 1991). (Right) An x-ray photograph of an Ad showing the capsid and the
dissociated fibre proteins (Joklik, 1988).
b) Genome Structure
Adenoviruses have linear, non-segmented, double-stranded DNA, 30 kbp to 44 kbp in
length (size differs among groups), with short inverted terminal repeats flanking the coding
regIon. Genome structure (cross-hybridization, restriction map) is one of the characteristics used
to assign viruses to groups (70% to 95% homology within groups, 50% to 60% homology
between groups). The left and right terminal sequences are short inverted repeats (100 to 140 bp)
which playa role in DNA replication. There is a 55kd protein covalently attached to the 5' end of
each strand (reviewed in Fields et al., 1996).
The viral genome has been divided into early and late units (Figure 3), with four early
units (E1A, EIB, E2A, E2B, E3, and E4) and five late units of mRNAs (LI to L5). The genes
transcribed give rise to multiple RNAs resulting from differential splicing and sometimes from
the use of different poly(A) sites (Berget et al., 1977). Structural polypeptides with their
proposed functions are listed in Table 2.
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Table 3: Ad polypeptides.
List of the known Ad polypeptides, their size and possible functions. These functions
were suggested based on studies done on Ad2 and Ad5 (compiled from Fields at al.,
1996 .
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Figure 3: Diagrammatic representation of Ad2 transcription and translation.
Early transcription regions are labelled E1 through E4 and late transcription regions are
labelled L1 through L5 (reviewed in Fields et al., 1996).
B. Life Cycle
The life cycle of adenoviruses starts with attachment to the host's cellular receptor,
penetration, transport to the nucleus, and finally DNA transcription (reviewed in Pettersson and
Roberts, 1986). Transcription of adenoviruses has been assigned to two sections, early and late,
which are divided by the start of DNA replication. The early stage immediately follows
adsorption of the virus to the cell membrane and penetration, and includes transcription and
translation of the four early regions. The onset of DNA replication is accompanied by the
initiation of the late gene transcription. Once all the structural proteins are produced, viral
assembly begins and, within 36 hours post-infection, cell lysis occurs (Shenk, 1996). The viral
progeny repeat the cycle by infecting neighbouring cells.
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c. Adsorption and Entry
The "knob" bound to the end of the Ad's fibre protein is thought to mediate viral
attachment to the host cell since soluble fibre proteins have been shown to inhibit viral
attachment (Defer et al., 1990). The cellular receptor still remains unknown except for Ad2 and
Ad5 where the cellular receptor CAR (Coxsakie Ad Receptor) used by the Coxsakie B viruses
was shown to be also used by Ad2 and Ad5 (Bergelson et al., 1997). Furthermore, the fact that
different serotypes differ considerably in their knob proteins' amino acid sequence and length
seems to indicate that different serotypes attach to different receptors on the cell membrane (Kidd
et a/., 1993). Internalisation of the virus is mediated by a cellular receptor, integrin, which
interacts with the RGD (Argenine-Glycine-Aspartate) amino acid conserved sequence on
polypeptide ill of the penton base (Wickham et al., 1993). Following adsorption, the virus is
internalised through receptor-mediated endocytosis (Varga et aI., 1991). Adsorption and
internalisation is a two-step process, where both interactions of the knob protein and the penton
base are required for successful viral intemalisation.
Internalisation of adenoviruses is very efficient, where about 85% of the adsorbed viruses
are internalised. The viruses contained within the endosomes, then move to the cytosol. The
endosomal pH seems to playa role in the viral movement to the cytosol before the formation of a
lysosome (Mellman, 1992). Forty-five minutes post-infection, the viral genome, free of hexon
proteins, is transferred through the nuclear membrane. Even defective Ad viral particles are able
to facilitate non-viral macromolecules into mammalian cell lines through receptor-mediated
endocytosis (reviewed in Hitt et al., 1997).
The capsid and the core proteins are dissociated in an orderly manner, where the first
proteins to dissociate are the fibre and the penton base; after penetration to the cytoplasm, the
virus loses proteins VI and Vill, which provide abridge between the core and the capsid (Greber
et al., 1993). Soon after, the hexons and pIX are destabilised. The DNA binding proteins, V and
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VII, are thought to be retained during genome entry into the nucleus, which occurs through
nuclear pores (Fredman and Engler, 1993).
D. Transcription
Ad transcription, which occurs within the nucleus of the host cell, has been divided into
two phases, early and late (Table 4), and they are separated by the onset of DNA replication. The
products of the early regions control the cell cycle, block apoptosis, control gene expression and
DNA replication and antagonise the host's immune response to destroy infected cells. The early
phase takes between five to six hours in Hela cells (reviewed in Petterson and Roberts, 1986),
after which DNA replication is initiated and expression of the late gene can be detected. This is
followed by the assembly of progeny virions. The whole cycle takes between 20 to 24 hours for
completion, with cell death occuring 30 to 40 hours post infection (Douglas et al., 1997).
Although the early genes are expressed in the "early" stage of infection, they continue to
be expressed throughout the "late" stage of the virus life cycle. There is also a low level of
expression from the major late promoter soon after infection. A delayed early stage has been
suggested for the proteins IVa2 and IX, which begin to be expressed at a stage following early
gene expression, but before the initiation of late gene expression (Pettersson et al., 1986).
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Table 4: List of known AdS transcribed regions.
The stage and direction of transcription of early and late regions are listed (Doerfler,
1996 .
1. Early Transcription
a) E1A
The earliest transcription of the £1 region occurs about one hour post-infection and
encondes at least five mRNAs, two expressed in the early stage of transcription and and three in
the late stage. The early EIA products, 13S (289 amimo acids) and 12S (243 amino acids)
(reviewed in Shenk, 1996), are produced from the same mRNA through differential splicing
(Harlow et al., 1985). These proteins play a wide range of roles during infection, such as
induction of DNA synthesis, induction of mitosis (transformation), and trans-activation of viral
genes. EIA controls EIB, E2, E3, and E4 mRNA accumulation. However, it cannot itself bind
DNA; instead, it seems to activate cellular proteins which bind to viral sequences within the
early region promoters.
In vitro, EIA proteins co-operate with EIB proteins to immortalise primary cells
(reviewed in Fields et al., 1996). EIA expression, on its own, is not sufficient to immortalise
primary cells. EIA products induce apoptosis by stabilising p53 protein and causing it to
accumulate inside the nucleus. The high levels of p53 protein inside the nucleus prevent cell
cycle progression and cause cell death (Donehower et al., 1992). The specific mechanism by
which p53 causes apoptosis is not well understood.
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EIA 128 and 138 mRNA contain 3 highly conserved regions among different
adenoviruses, namely CRI to 3. These products have been shown to interact with a cellular
protein of the p300 family (Cook et al., 1996). This "p300 family" of proteins interacts with a
variety of enhancer-binding transcription factors. EIA appears to act by linking these factors to
components of the transcription machinery, therefore promoting DNA transcription.
b) E1B
Early region IB codes for two proteins: a 19kd and a 55kd protein. The 19kd product is
needed for preventing cellular apoptosis, since it inhibits p53 induced cell death and co-operates
with EIA. The cellular phosphoprotein p53 is a sequence-specific DNA binding protein and a
transcription factor. P53 is capable of both trans-activating and repressing cellular DNA
transcription. It can also suppress oncogenic transformation, negatively regulate cell cycle
progression and induce apoptosis (yogelstein and Kinzler; 1992). All of these roles have been
shown to participate in the tumour suppressor function ofp53.
EIB has also been shown to co-operate with EIA products to oncogenically transform
primary cells in vitro (Finlay et al., 1989). EIA and EIB are both required for full transformation
and tumour formation caused by AdI2 in rodents. The EIB 55kd product promotes the cell to go
into the S phase of the cell cycle, which enhances viral DNA replication. Transformation is
accomplished by inhibiting EIA-induced p53-dependent apoptosis. The 55kd protein of EIB
binds to the trans-activation domain at the N-terminal of p53 and prevents its transcription
activation property (Sabbatini et al., 1995). Mutant analysis of the EIB 55kd protein revealed
that binding affmity to p53 correlates with the ability of EIB to transform primary cells in
culture. In a study by Bishchoff et ale (1996), an Ad deficient in the EIB region was able to
selectively replicate in p53-deficient human tumour cells. Therefore, the virus was able to grow
in these cells and cause their lysis.
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c) E2
E2 codes for proteins needed for DNA replication and packaging. E2A codes for the 72
kd DNA-binding protein (DBP), a histone-like protein, thought to playa role in DNA packaging.
E2B codes for the 140kd DNA polymerase (Ad-pol) and the 80 kd terminal protein precursor
(pTP) (reviewed in Hitt et al., 1997). E2 transcription switches between two promoters, "early"
and "late", where the "early" promoter is used in the early phase of transcription and the "late"
promoter is used during the late phase of transcription. The reason for the switch between
promoters remains to be identified (reviewed in Swaminathan and Thimppaya, 1995).
d) E3
E3 gene products interfere with immuno-surveillance of the host's immune system. E3
codes for 9 overlapping mRNA's that are generated by differential splicing and the use of
different poly-A sites (reviewed in Hitt et al., 1997). Eight proteins have been identified. Two
proteins, the 19kd and 14.7 kd proteins, have been studied in more detail. The 19kd protein is
one of the most abundant early proteins and consists of 142 amino acids. It interacts with and
prevents class I major histocompatibility complex (MHC I) from leaving the rough endoplasmic
reticulum, thereby preventing infecting cells from presenting viral antigens on the cell surface
(Deryckere et al., 1995). This process prevents Tc cytotoxic cells from recognising infected cells
and consequently they never initiate MHC-dependent cell lysis. In contrast, the 14.7 kd protein
protects infected cells from cytolysis triggered by tumour necrosis factor a (TNFa).
The interaction between MHC class I and the E3 19kd is not covalent and does not
involve disulfide bonds or carbohydrates; however, the internal disulfide bonds present in the E3
19kd protein are necessary for binding (Sparer and Gooding, 1998). This protein is able to bind
to a wide range of alleles in human and mouse hosts with differing affmities (Cox et al., 1990).
The initial speculation was that the 19kd protein binds to one of the conserved regions of MHC
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class I proteins; however, the binding regions were mapped to <Xl-and <X2-helices of the variable
domain in MHC class I proteins (Beier et al., 1994). E3 products are not required by the virus to
grow in cell culture.
e) E4
The E4 transcription region is less characterised than the other early regions. At least
seven open reading frames have been attributed to this region (reviewed in Hitt et al., 1997). £4
has been shown to playa role in promoting primary cell transformation in vitro by co-operating
with EIA and EIB. Moreover, E4 products playa role in preventing cellular mRNA transport
from the nucleus to the cytoplasm of infected cells. E4 is also involved in enhancing viral DNA
transcription by co-operating with a 19kd DNA binding protein. A recent study by Nevels et al.
(1997) revealed a 34 kd protein encoded by open reading frame 6 (ORF 6) of the E4 that stably
binds the carboxy-terminus of the cellular protein p53 and that also interacts with the 55 kd EIB
protein. The carboxy terminus of p53 protein plays a role in regulating DNA binding, nuclear
localisation, recognition of DNA damage; it may also have a role in causing cellular apoptosis
(Soussi and May, 1996).
f) VA RNA
The adenoviral genome codes for the so-called "VA" RNAs (virion associated RNAs).
However, contradictory to what the name indicates, the VA RNA molecules are not part of the
virus structure, but they have been detected in large amounts in infected cells (reviewed in Fields
et al., 1996). These RNAs are thought to act as translational activators. They block the protein
kinase that phosphorylates and inactivates the eukaryotic transcription factor eIF-2, thereby
blocking the virus-inhibition activity of interferons, which activate the protein kinase (reviewed
in Hitt et al., 1997).
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E. DNA Replication
Adenoviral DNA replication begins about 5 hours post-infection in Hela cells (Challberg
and Kelly, 1989) and requires both viral encoded and cellular factors. Only -one of the strands in
the double stranded DNA genome serves as a template, resulting in a displaced single strand and
a double stranded hybrid duplex. The displaced single stranded DNA then forms a "pan-handle""
structure through the annealing of its inverted tenninal repeats (Figure 4); this double stranded
structure is then recognized by the replication proteins and allowed to go through the replication
cycle, resulting in a full double stranded hybrid DNA duplex structure (reviewed in Van der
Vliet. 1995).
3cba
\:BA
AB~5'
abc 3'
24
1 ~c 5'
3_cb_a ~g~ 5'
\:BA abc 3'
1
3~2--------------------------------~~ 5'
\:BA abc 3'
+
3'
cba
3'cba
.----------------~5 CBA
AB<; 5'
AB~'
3' ,
c C
b B
a A
5~13L\-----------~
3'cba
/
ABC- 5'
Figure 4: Schematic diagram showing Adenoviral DNA replication.
One of the strands serves as a template, which results in a displaced single strand.
The displaced strand forms a panhandle structure through the annealing of inverted
terminal repeats (ITR's). The double stranded structure is then recognised by the
transcription machinery. Upper and lower case letters are used to indicate
complementarity of the ITR's where capital letter orientation will bind to the lower case
orientation only (reviewed in Van der Vliet, 1995)
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F. Late Transcription
Late transcription is initiated subsequent to DNA replication. The late regIon IS
comprised of five families, namely: L1 to L5.
1. Late region
The late regions' proteins make up the capsid components. Transcription of the late
region starts from the MLP (major late promoter) and produces a single mRNA product that is
differentially spliced into the five different families of mRNAs (Shaw and Ziff, 1980). The
activity of the major late promoter (MLP) increases lOO-fold after the onset of DNA replication
and it is thought to be activated by the MLP transcription factor (reviewed in Fields et aI., 1996).
2. Virus Assembly
Virus assembly starts with the formation of pentons and hexons capsomeres in the
cytoplasm. The process continues in the nucleus through a series of intermediate structures that
consist of the DNA genome, TP, pV, pVII~ and the polypeptide mu. Proteolytic processing
results in the final mature virus particles which are released through cell induced lysis (reviewed
in Shenk, 1996).
G. Bovine. adenovirus
Most of what is konwn about Ads is based on studies done with Ad2 and AdS. BAVs on
the other hand, are less studied and this section will summarize what is currently known about
them.
Bovine adenoviruses (BAVs) were first isolated in 1959 (Klein et aI., 1959). They have
been classified into two subgroups, which are further divided into nine serotypes based on the
presence of complement-fixing antigen, grow1h rate, and their ability to grow in different primary
and established cell lines. Subgroup 1 contains serotypes 1, 2, 3, and 9 while subgroup 2
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contains serotypes 4 to 8. The organisation of the BAV genome resembles that of Ads. BAVs
are spread worldwide causing respiratory and gastrointestinal illnesses in bovine species
(Mattson et al., 1988).
1. Bovine adenovirus type 2
BAV2 is divided into two subtypes, namely A and B (Belak and Palfi, 1974). These two
subtypes differ in their permissivity in cattle and sheep. Subtype A can only infect cattle, while
subtype B can infect both cattle and sheep. They also differ in their restriction endonuclease
pattern and in hemagglutination properties where subtype A hemagglutinate bovine erythrocytes
and subtype B hemagglutinate rat erythrocytes (Belak et al., 1983).
H. Current Uses ofAden0 viruses
Most adenoviral vectors are based on AdS. Adenoviral vectors are either helper
independent (replication-competent) or conditional helper-independent (replication-deficient in
non-complementing cells) recombinants. Replication-competent vectors have been successfully
used in animal models to induce antibody, secretory and cell-mediated immunity against HBV,
CMV, and RSV. Replication-deficient vectors, missing the El region (£1-), are an attractive
delivery tool in gene therapy, since the virus' only purpose is to deliver the gene to the target cell
(reviewed in Hitt et al., 1997).
The most common Ad vectors carry deletions in either El, E3 or both. Other vectors
such as E2 and E4 have also been generated (Amalfitano et al., 1996); however, they are not as
common as the EIIE3 deletion viruses. Recent studies suggest keeping E3 intact to allow the
virus to hide from the immune system, therefore giving it a better chance of delivering the gene it
is carrying. The El deletion vectors are favoured, since they have the added safety feature of
lacking the El region that in Ad12 can cause oncogenic transformation of primary cells in
rodents.
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Today's generation of gene therapy viral vectors is limited in that they are being
destroyed by the humoral and cellular immune response of the patients. This greatly affects the
re-administration of the same viral vector. The other limitation of adenoviruses is that they infect
a wide range of cell types, which limits the targeting of specific cell types or organs (Douglas,
1997).
1. First Generation Adenoviral Vectors
First generation adenoviral vectors were based on human Ad2 and Ad5. These viruses
have been well studied and characterised. They have been shown to share close to 950/0
homology (Chroboczek et ol., 1992). Human Ad2 and Ad5 belong to group C, which does not
cause tumours in rodents. Viral vectors based on these serotypes carrying E1 deletions have an
extra safety feature, as previously described.
Ad viruses can carry up to 105 % of the wild type genome size (Bett el af., 1993).
Therefore, Ad vectors can accept up to 2 kb of foreign DNA without any deletions. Deletions in
both Eland E3 regions allow for up to 5 kb-inserts. The largest E3 deletion accomplished in Ad5
was 3.1 kb (Bett et af., 1994). E 1 deleted viruses require the 293 packaging cell line (Figure 5), a
human embryonic kidney cell line transformed with the E1 region of Ad5 (Graham et af., 1977).
Target CellsPackaging Cell Line
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Figure 5: Schematic representation of the generation of E1-deleted Ads.
(a) Ad genome with 0% at the left end and 100% at the right end. The diagram
indicates the direction of the Early and the Late region transcriptions. (b) A
diagrammatic representation of an adenoviral mutant's genome. The genome carries
an E1 deletion with a transgene inserted in its place. The transgene is controlled under
a constitutive promoter to control the gene's expression. The figure also shows the
absence of Early or Late region expressions, caused by the absence of the E1 region.
(c) This part of the figure represents the process of rescuing a recombinant mutant
virus, where the modified genome from part (b) can be transfected into a packaging cell
line, which provides the E1 products in trans. DNA transcription and translation of the
viral DNA results in the formation of a complete assembled virus, which carries the
transgene and its promoter. The resulting virus can then be used to infect target
tissues, or cells in order to transfer a gene for the sake of gene therapy or vaccination.
The attenuated E I-deleted Ad vectors have been shown in several studies to result in lower levels
of foreign gene "expression in vitro when compared to E3-deleted replication-competent vectors
(reviewed in Hitt et af., 1997), with the exception of one study by Levrero et al. (1991) where
both types of vectors resulted in equal levels of expression. E I-deleted Ad vectors are more
suitable for in vivo gene therapy. However, for in vitro recombinant gene expression, E3-deleted
replication-competent viruses have been shown, by most studies, to result in higher levels of
recombinant protein expression.
E1 replacement genes have been shown to be expressed when present in both leftward
and rightward orientation, although the rightward orientation has been shown to result in a higher
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level of expression (reviewed in Hitt et aI., 1995). In replication competent E3-deleted vectors,
genes lacking strong promoters were shown to be expressed mainly in the rightward orientation
(Mittal et aI., 1993; Yarosh et al., 1996).
There are two main problems associated with the first generation of Ad vectors, when
used in gene therapy. The first problem is the presence of low levels of DNA viral transcription
in attenuated EI-deleted vectors observed both in vivo (Yang et al., 1994) and in vitro (Spergel et
aI., 1992). This low level of viral protein expression is partly responsible for activation of the
immune system, which results in the elimination of infected cells in gene therapy trials (Rich et
al., 1993). Other contributors to immune system activation are the presence of adenoviruses
themselves in the initial inoculum (McCoy el al., 1995) and, in some instances, the foreign gene
product itself (Tripathy el aI., 1996). The second problem concerns \\lith the propagation of the
EI-deficient Ad vectors. These viruses must be grown in the packaging cell line 293, which
provides the E1 products in trans. However, the cell line also provides enough overlap between
the Ad5 DNA in the cells and the vector's DNA to generate replication-competent Ad viruses
through homologous recombination. The wild type revertants, depending on the replication rate
of the mutant vector, might be able to outgrow the viral vector of interest (Lochmuller et al.,
1994). The presence of wild type revertant viruses, even at low levels, may pose a serious
problem in gene. therapy by activating the immune system or by acting as a helper virus for the
replication of the attenuated viral vector. That could result in inappropriately high levels of
transgene expression which may he harmful to the patients (reviewed in Hitt et aI., 1997).
2. Second Generation Adenoviral Vectors
The second generation Ad vectors carry modifications in order to correct the flaws of the
first generation vectors. One of these modifications is the development of added deletions, such
as the one developed by Armentano et al. (1995) which contained a deletion within E4. It is still
I
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not known how this modification to the E4 region will affect the basal level expression of the late
regions, but such modifications will not eliminate the immune response against the original
inoculum or to subsequent administrations of the vector (Kaplan et al., 1996).
E2A products play a role in viral DNA replication and packaging. In a study by
Engelhardt et ale (1994), an Ad carrying a mutation in the E2A region resulted in a temperature
sensitive E2A 72kd DNA binding protein. This mutant showed a significant decrease in late
gene expression levels when grown at 37°C. In addition, homologous recombination in the 293
cell line, which would normally result in wild type revertants, resulted in a virus that was
completely impaired in expression of the late genes.
Wild type Ad viruses can complement and allow for the replication of attenuated E1-
deleted vectors. This characteristic can pose a potential hazard, especially in vivo, when used as
a gene therapy tool (reviewed in Hitt et al., 1997). In a study by Imler et a1. (1995), an E1-
deleted Ad5 vector was further attenuated by introducing a mutation in the cis-acting
encapsidation signal in the left end of the genome (270 bp to 346 bp). The mutation resulted in
an Ad5 vector with impaired incapsidation by a factor of three to ten, when compared to the wild
type Ad5. Consequently, in the case of mixed infection with a wild type virus, the recombinant
virus will be outgrown by the wild type, thereby, eliminating the chance of spreading the
recombinant virus. Although careful monitoring must be exercised when growing this virus in
293 cells, it has an added safety feature to prevent the inadvertant dissemination of recombinant
Ad viruses to other tissues within the patient or to other individuals.
Alternative packaging cell lines that would prevent reversions to wild type have been
proposed as a modification of the first generation Ad viral vectors (discussed Wlder "Packaging
Cell Lines"). One of the major areas of research of the use Ad viral vectors is in treatments of
cystic fibrosis.
31
Cystic fibrosis results from a mutation in the cystic fibrosis transmembrane conductance
regulator gene (CFTR). Mutation in this gene results in a non-functional ion channel that leads
to an imbalance of chloride ion concentration in the epithelia (Collins, 1992).
Replication defective Ad2 and AdS-based viral vectors carrying the CFTR cDNA showed
various degrees of success in delivering the healthy copy of the gene. The problems encountered
were caused mainly by the humoral and cellular immune responses to the vector and to the
infected cells. Although the current generation of gene therapy vectors is thought to be
completely crippled in terms of replication, a low level of trans-complementation still occurs,
resulting in low levels of DNA replication. Another possibility is that the gene being delivered
itself, when expressed could, elicit an immune response causing the destruction of the infected
cell carrying it. However, the most obvious obstacle is the priming disposition of an immune
response that would neutralise any subsequent administrations (Bout et ai., 1994).
Throughout the studies, several observations were made, such as: the occurrence of
inflammation and transient expression of the transferred CFTR gene; subsequent attempts to
restore expression by a second administration was usually unsuccessful (reviewed in Johnson,
1995).
3. Generating wild type-free Adenovirus vectors
Recombinant Ad vectors were initially developed and used for eukaryotic gene
expression and vaccine development in vitro (Gomez-Foix et al., 1992). However, animal
studies revealed the possibility of using recombinant vectors for gene therapy, with the first trial
in humans utilising a vector carrying the CFTR gene (Crystal et al., 1994). Recombinant vectors,
especially those carrying El deletion and £1 substitutions, are grown in 293 cells (human
embryonic kidney cells transformed with fragmented Ad5 DNA and determined to be carrying
0% to 12.5% ofthe genome).
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Viral vectors used for gene therapy in vitro evaluation and clinical studies must be wild
type-free. However, as previously mentioned, growing E1 deletion Ad mutants in 293 cells
results in reversion to wild type Ad through homologous recombination between the viral DNA
and the integrated Ad5 left end segment. A study by Zhang et ale (1995) resulted in the
development of a PeR-based method, which can be used to detect 1 pfu of wild type Ad virus in
109 pfu of recombinant virus. Another method for detecting contaminants was based on the fact
that only wild-type Ad viruses are able to grow in Hela cell lines. Therefore, Dion et al. (1996)
used a stock of recombinant Ad vectors to infect Hela cells and, based on the amount of virus
produced, they were able to extrapolate the amount of virus present in the original stock. This
system can also be used to detect contaminants that result from laboratory handling or air-borne
spreading.
To avoid having to deal with revertants, the alternative route would be to develop a
packaging cell line that complements the missing E1 proteins, but without allowing any extra
DNA sequences, so as to prevent overlapping and subsequent homologous recombination. This is
part of the objective of this study.
In recent studies, new cell lines were developed to complement the El, E4 (Brough et al.,
1996) and E1, E4, pIX (Krougliak and Graham, 1995) of AdS. These cell lines were based on
the established 293 cell line. Although these cell lines still contain the overlapping E1 region,
they cannot allow for full wild-type revertants, since the E4 and pIX regions do not allow for
homologous recombination. Ad vectors missing E1, E3, E4, and pIX are able to grow in the
newly established cell lines and they can take up to 11 kb of inserted foreign DNA. This new
modification of the 293 cell line allows for the production ofAd vectors that can carry larger size
foreign DNA fragments, that are safer and that lack helper function for adeno-associated virus.
In another similar study (Amalfitano et al., 1996), a 293-derived cell line was constructed
to complement E1 products and Ad2 DNA polymerase. The enhanced feature of this cell line is
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the inability of the virus to replicate its DNA in vivo. This is desirable, since, otherwise, cells
that contained the inserted gene of interest would be eliminated. Human gene therapy trials have
shown that the transient expression of foreign DNA is correlated with low levels of viral DNA
expression, which then leads to an immune response and eventually the elimination of the
infected cells.
A new cell line, designated 911 (Fallaux et al., 1996), was produced by transfection of
human embryonic retinoblast cells with an Ad5 carrying plasmid vector. The new cell line
prevents reversions to wild type, since it only carries DNA from nt79 to nt5789, but it still shares
many of the properties of the 293 cell line, such as its ability to support a high level of
recombination and recombinant virus production. Other cell lines, based on human lung
carcinoma (Imler et al., 1996) and designated as PTG6564-17 and PTG6559-5, include the Ad5
sequences from nt505 to nt4034. These cell lines are inferior to 293, in that they are about ten
times less effective in supporting the growth of El-deleted recombinant viruses. However, these
cell lines were not tested for their ability to support homologous recombination in Ad vector
production.
4. Gene Therapy
Somatic gene therapy involves the insertion of the correct configuration of a gene into an
individual's somatic cells so that the normal gene product is produced to correct a metabolic
disorder. Only a certain cell type is normally targeted by gene therapy. This can be done in two
ways. The first method is done ex vivo, where cells from the affected tissue are removed and
cultured in vitro; the gene is then introduced into these cells to correct the defect. Once the cells
are grown to large enough quantities, they are transplanted back into the patient. The other
method for gene therapy is done in vivo, where the gene is transferred to the target site without
the need for tissue removal or culturing cells in vitro (Densick and Schuchman; 1998).
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Human gene therapy, first approved in 1989, has relied mainly on virus-based delivery
systems and has had a great influence on the generation of replication-deficient viral vectors
(Wilkinson and Borysiewicz, 1995). The choice of the method used for gene delivery should
address the risk involved, as well as efficiency and specificity of the virus (Table 5). Currently,
there are over 140 human gene therapy protocols approved for clinical testing (reviewed in Hitt et
aZ., 1997). Most of these protocols use retroviral, adenoviral or adena-associated viruses, while
some use direct DNA injection or lipofection as a method ofDNA delivery.
Retroviruses have been widely used in gene therapy. These vectors have been developed
as replication-deficient viruses capable of stably integrating into the chromosome (reviewed in
Wilkinson et aZ., 1995). These viruses are uniquely suited for gene therapy since integration into
the host cell genome is an obligatory part of their life cycle. However, they still have serious
limitations: (1) they require dividing cells for stable integration, which limits their use in vivo,
(2) insertional mutagenesis might arise from the random integration step, (3) low viral titers are
produced from both the wild type and mutants grown in packaging cell lines, (4) a short shelf
life makes it difficult to produce the virus in large quantities to be stored or shipped, and (5)
recombination between the viral vectors and endogenous retroviruses might occur.
Adeno-associated viruses (AAV) are non-pathogenic parvoviruses that requIre co-
infection with an Ad, or certain members of the herpes virus family, to complete their life cycle
(reviewed in Fields et aZ., 1996). In the absence of a helper virus, AAVs integrate at specific
sites within the genome and exist in a latent state up.til the cell is infected with a helper virus.
The virus then replicates and undergoes a lytic cycle. This family of viruses has several
advantages (Kohn et aZ., 1990): (1) AAVs do not cause any known diseases in humans, (2)
they have a broad host range and do not require dividing cells in order to integrate, (3) the wild
type virus integrates at a specific site (chromosome 19 in humans), and (4) more than 95% of the
genome can be removed, allowing for foreign gene insertion. However, the use of AAVs as tools
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for gene therapy also carries some disadvantages (Kohn et al., 1990; Densick and Schuchman,
1998): (1) they cannot carry sequences larger than 5kb, (2) integrated AAVs can be activated
by co-infection with the wild type AAV or a helper virus, causing the integrated provirus to be
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released, (3) permanent packaging cell lines have not been developed yet, and (4) site specific
integration does not occur with the recombinant AAVs.
The herpes virus is also an attractive tool in gene therapy, frrstly, due to the fact that it can
be used to target the central nervous system, as well as its ability to infect non-dividing cells, the
production of high titer viral stocks and its ability to carry large size inserts of foreign DNA (up
to 30kb) (Breakefield, 1993). Despite the advantages, the herpes virus protocol for gene delivery
is still under development, since the vectors produced have been shown to be cytotoxic, in vivo
infection efficiency is low, and there is limited spread of the virus from the site of injection
(Desnick and Shuchman, 1998).
Table 5: List of gene delivery methods.
Table shows advantages and disadvantages of the different techniques used to deliver
genes in gene therapy studies. Compiled from Kessler et al.(1996), Desnick and
Schuchman 1998.
Recombinant Vectors
C totoxic
Problems associated with viruses, their side effects and possible risks, has led to the
development ofnon-viral based gene delivery systems. Systems employing liposomes and DNA-
protein conjugates have been investigated as alternatives to the use ofviral vectors.
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Liposomes are lipid bilayer vesicles that, depending on the method of preparation, may
consist of a single bilayer or multiple bilayers surrounding an aqueous center (FeIgner and
Rhodes, 1991). The vesicles can range in size from a few nanometers to micro~eters. Positively
charged liposomes have been used to carry over DNA. Upon injection into a patient, these
vesicles pose very little risk of an immune reaction or cause of a disease (Smith et al., 1993).
The inherent disadvantage of liposomes is the lack of specificity or specific cell-type targeting.
The other problem associated with these vesicles is the lack of stability upon injection into
animals, where they either break down or form aggregates. Moreover, liposomes are not as
efficient as viruses in delivering genes to the target cell nucleus (Smith et al., 1993).
5. Viral Vaccines And Genetic Immunisation
Recombinant vaccines are very similar to viral vectors used in gene therapy in that they
both have been altered to carry and deliver foreign genes. However, the immune response, which
is a major issue in gene therapy, is actually the target for recombinant vaccines. For vaccination,
it is necessary to express the foreign gene long enough to stimulate an effective and long lasting
immune response (reviewed in Hitt et al., 1997).
Viruses are obligate intracellular parasites. Consequently, any interference with their
entrance into the host's cell would prevent them from causing a disease. Blocking the initial
viral-host cell interaction is the most convenient point of protection. Therefore, antibodies that
recognise viral surface proteins would confer immunity against the virus. The antibodies of the
host do not need to recognise all the proteins on the viral capsid; in fact, one subunit of the viral
capsid protein is all that is needed to provide immunity (reviewed in Descamps et al., 1996).
Immunisation against foot and mouth disease was one of the first methods to employ
single synthetic peptide technology to provide protective immunity (Babiuk and Phillips, 1989).
However, this technique carries a disadvantage due to the fact that viruses can easily mutate,
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rendering the subunit vaccine useless in terms of providing protective immunity against the
infectious agent.
The other option for protection is to use viral proteins that are targeted by cytotoxic T
cells (CTLs), which lyse infected cells before the virus has completed its replication cycle. This
will in turn reduce the amount of virus present and the subsequent chance of a clinical disease.
Such vaccines have been shown to provide an enhanced protective immunity in the case of
orthomyxovirus, where the nucleocapsid protein , conserved among different strains of influenza
viruses, was shown to be a major target of CTLs (Babiuk et al., 1996). Consequently, even if the
virus experiences mutations or an antigenic shift in regions targeted by monoclonal antibodies,
the CTLs would still recognise infected cells and cause their lysis.
Once the desired proteins have been identified, they can then be produced in large scale in
either a prokaryotic or a eukaryotic system. Prokaryotic systems have been shown to produce
viral proteins that can confer protective immunity in vivo; however, due to post-translational
modifications, eukaryotic systems are more suitable for producing viral glycoproteins.
Eukaryotic systems such as yeast, mammalian cell lines, insect cell lines and, recently, plants
have been used for such purposes. All these systems have been shown to be very efficient at
producing viral glycoproteins at high levels as well as maintaining the conformation of the
proteins, which is critical for an effective immunisation. Hepatitis B was the fIrst licensed
recombinant vaccine that was produced in yeast (Babuik et al., 1996).
The proteins could be produced in a cell line either through constitutive expression,
where the gene that codes for the protein is integrated in the cellular genome, or through the use
of a recombinant virus. In the first case, there may be problems associated with constitutive
expression, such as toxicity to the cell expressing the protein; furthermore, unless the protein is
secreted, the purification procedure might be very costly. The second option, which is to use a
recombinant virus to carry the foreign gene, eliminates the toxicity aspect of the previous
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method, but faces the problem of sample purification to produce a 100% virus-free vaccine
(Kowalski et al., 1993).
A novel vaccine production strategy was developed by using recombinant baculoviruses
that carry foreign genes (Kang, 1988). They can be used to infect silk worms, resulting in the
secretion of 1 mg of the desired protein from a single larvae. Further studies on the secreted
proteins are being done to assess whether they had the appropriate post-translational
modifications.
The debate regarding the use of live vaccines versus attenuated vaccines continues, where
live incapacitated viruses, missing crucial genes, are thought to be safer options than attenuated
vaccines. This is due to the fact that the genetic basis of attenuation in live attenuated vaccines is
not very well understood and the risk of developing the disease is still possible. One of the first
live vaccines to be available commercially was the pseudorabies virus, which contained a
specific deletion in the thymidine kinase (TK) gene and/or viral glycoprotein (gC or gE gene)
(Kit et al., 1987). The virus was able to replicate in vitro, but was not able to complete its life
cycle in vivo, thereby, greatly enhancing the safety aspect of the vaccination procedure.
Vaccinia virus is a member of the poxiviridae family, which, unlike most DNA viruses,
replicates in the cytoplasm of infected cells by encoding their transcription and replication
machinery ( reviewed in Fields et al., 1996). These viruses have a large genome of 185 kbp,
allowing for large inserts of foreign DNA. Among their other advantages as recombinant
vaccines are the following: they are readily administered, they confer long term protection, they
are inexpensive, and they provide long term stability of the virus (Wilkinson and Borysiewicz,
1995). Although side effects have been well characterised, serious complications do occur.
These complications include secondary spread of the lesion, rash, progressive vaccinia, aczema
vaccinatum and encephalitic disease. Vaccinia mutants, carrying deletions in genes that are not
essential for in vitro replication or expressing interleukin type 2 (IL-2) to stimulate the immune
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system, are potential solutions to side effects which are currently being explored. Such
modifications could improve the benefit-to-risk ratio, especially in high-risk groups including
those with immWle system disorders (Wilkinson and Borysiewicz, 1995).
Retroviruses, on the other hand, are not suited to be used as recombinant vaccine delivery
systems, since they produce low levels of expression and they are potentially oncogenic due to
their random integration. Moreover, they can be rescued by endogenous retroviruses. However,
the main disadvantage of retroviruses is their requirement for dividing cells (reviewed in Fields
et al., 1996).
Ideal viral vaccines should provide a 100% success rate in preventing subsequent viral
infection; however, complete protection is not realistic. The realistic ideal vaccine should have a
success rate of over 90%. The vaccine should provide long-term protection within a few weeks
of a single administration, thereby reducing the cost of re-immWlisation. Furthermore, the
vaccine needs to be safe, in that it will not cause adverse reactions, disease, or interference when
simultaneously administered with other vaccines. The vaccine should also be genetically and
thermally stable (reviewed in Hitt et a/., 1997).
In veterinary medicine, most of the pathogens enter via the mucosal surfaces; therefore,
ideal vaccines should stimulate mucosal immunity, which would be best induced by intranasal or
oral delivery. Thus, the vaccine should be designed to be delivered by mucosal routes (Babiuk et
a/., 1996). In the veterinary field, the cost of vaccination is a crucial consideration, where the
cost of a single vaccination should not exceed a few cents per administration, especially in
developing cOWltries.
Genetic immunisation employs the use·ofnaked plasmid DNA as the source of the coding
region for the vaccine. This technology, described as the "revolution in vaccine biotechnology"
(Ulmer et al., 1996), has had a strong foundation, built on the observation that when plasmid
DNA was introduced into an animal's tricep muscle (Wolff et al., 1990), the genes were
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expressed for an extended period of time. This would allow enough time for the immune system
to recognise the foreign proteins and produce the appropriate immunity against it. This technique
has been used to show that genes from different sources (bacterial, viral, reporter genes, etc.) can
be expressed and used in different animals, ranging from fish, chickens, rabbits, cows and non-
human primates (Babiuk et al., 1996).
The major advantages of this technology are: (1) the possibility of including several
genes from different sources on the same plasmid in order to induce protective immunity against
several infectious agents in one immunisation procedure, (2) the absence of the risk of
developing a disease following immunisation, (3) the achievement of the proper conformation of
the protein following antigen post-translational modifications and folding of the protein, (4) the
induction of both humoral and cellular immune responses, (5) the possibility of life-long
immunity (still under investigation), and (6) in the case of multiple vaccines, the lack of vaccine
incompatibilities (Babiuk et al., 1996).
6. Establishing Cell Lines
Immortal transformed cells have been widely used in studies involving oncogenesis,
differentiation and development, clinical neurology (Geller et al., 1991) and virology, where
they are employed as tools to generate viral vectors or to simply generate high titer viral stocks.
The first observation of the ability of Ad to transform cells was in 1962 when Trentin and
co-workers, showed that Ad12 was able to cause oncogenic tumours in newborn rodents. That
study generated a lot of interest and research into the possible link between adenoviruses and
human cancers. All subsequent research failed to reveal adenoviral DNA presence in human
tumours, but they did show that the E1 region of Ad12 had to be present in order for the virus to
cause a tumour in newborn rodents. Ad12 integration in the cellular genome is thought to be a
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non-sequence-specific insertional recombination, in which patch homologies are observed
between sequences from both the virus and from those of the cellular genome (Doerfler, 1996).
Senescence is a phenomenon that characterises the limited proliferative capacity of
normal mammalian cells. There are several models proposed for the causes of cellular
senescence. One model suggests that senescence is a process characterised by the accumulation
of abnormal macromolecules until cell division ceases (Bryan and Reddel, 1994). The
accumulation of such abnormal products (deaminated proteins and oxidised amino acids) has
been documented in senescent cells. Another view is that senescence is a programmed event,
since senescent cells have been shown to express new genes as well as repress normally
expressed genes (Goldstein, 1990). This theory was supported by a study where human
fibroblasts were fused with immortal human cervical cancer cells exhibited a limited division
potential in culture (Bryan and Reddel, 1994). The third theory explaining the case of senescence
proposes a role for the conserved telomeric sequences. The repeated sequence TTAGGG is used
by the DNA replication machinery during cell division. If this sequence is lost during successive
cell cycles, eventually the cell will be prevented from dividing. This growth arrest was suggested
to be linked to an activation of p53-dependent cell division arrest in response to DNA damage
(Dulic et al., 1994). While the phenomenon of senescence and the details of it have not yet been
determined, this limited cellular passaging capacity can be overcome by immortalisation in vitro.
Primary cells can be immortalised using a number of methods including the use of oncogenes,
growth factors (Spandidos, 1985), chemical carcinogens, and cellular genetic alterations (Gonos
and Spandidos, 1993). The immortalised phenotype really represents more of a decreased
differentiation potential than an increase in replication potential. Immortalisation is the first step
in tumourogenesis, while the second step is transformation. Viral (Ad £1 region, SV40 and
polyoma large T antigen as well as £6 and £7 of human papiloma virus (Bryan and Reddel,
1994) and cellular (ras, myc,fos,jun and some mutants ofp53 protein (Spandidos (editor), 1992)
42
oncogenes have been shown to have the ability to immortalise cells. The immortalising
oncogenes appear to eliminate the function of some cellular proteins, such as the retinoblastoma
and the normal p53 protein, which seem to prevent cell proliferation.
Normal cells have a limited number of passages in vitro (approximately 12 generations),
after which the cell culture appears to go into crisis resulting in cell death. Following
immortalisation, the cells exhibit a life-span of over 100 generations in culture, as well as
uninhibited growth, cloning in agar, growth on confluent monolayers and lower serum
dependence.
The second step in tumourogenesis is transformation. The events leading to
transformation are not very well understood; however, transformed cells have distinct properties
such as anchorage independence, the ability to grow in suspension, the loss of contact inhibition,
the ability to form foci in. culture, high saturation density, a low serum requirement, over-
expressed oncogenes or deleted suppressor genes, a modified extracellular matrix and the ability
to cause invasive tumours in vivo.
Oncogenes involved in immortalisation and transformation have different properties:
those capable of immortalising primary cells have the common feature of nuclear localisation,
while those capable of transforming cells have a mainly cytoplasmic localisation (Gonos and
Spandidos, 1993)
I. Prospects of SAVs for gene therapy and vaccine application
Bovine adenoviruses (BAVs) can be a successful mean of gene therapy, and viral vaccine.
They can be used, in veterinary medicine as well as in human medicine. In a study by Mittal et al.
(1995), BAV3 carrying the firefly luciferase gene in place of the E3 region was constructed.
Although BAV3 is non-permissive in humans, upon its infection in human (293) and bovine
(MDBK) cell lines, luciferase gene expression was detected in both cell lines. The application
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of non-permissive viruses in viral vaccine studies was shown to be successful in vaccinating dogs
(Prevec el al., 1990), skunks and foxes (Charlton el al., 1992) with a recombinant human AdS
viral vector carrying the rabies glycoprotein gene. A very low percentage of the population has
been exposed to BAVs. Therefore, the virus would have a better chance of delivering the gene
of interest without getting degraded by a pre-existing immune response.
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VII. Objectives of the Current Study
The primary goal of this research project was to establish a packaging cell line capable of
complementing the EI functions in trans. To achieve such a goal, the following number of
objectives ought to be undertaken:
1) Construction ofpCMV-El and establishing a cell line from embryonic primary cells
2) Construction of pCMV-E I-neo and establishing a cell line from established cell lines
3) Characterization of the constructed cell line in terms of the following:
a) Expression of E1 products
b) Expression of trasnfected DNA
c) Complemenation of E I-deletion mutant of bovine adenovirus type 2
4) Construction of recombinant BAV2 plasmids carrying the laeZ gene in place of the deleted
E1 and/or E3 region
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VIII. Materials and Methods
A. Bacterial strains
The bacterial strains used in cloning and propagation of plasmid DNA were Escherichia
coli (E. coli) DH5 a (Genotype: F-~80dlacZ~M15 ~(lacZYA-argF)UI69 deoR recAI endAl
hsdR17(rk-, mk+) phoA supE44 A- thi-I gyrA96 relAI; Life Technologies™ ) and XLI-Blue MR
(Genotype: !l(mcrA)183 !l(mcrCB-hsdSMR-mrr)173 endAl supE44 thi-l recAl gyrA96 relAJ
lac; Stratagene®). These E. coli strains were grown in Luria-Bertani medium (LB: 1% Bacto-
Tryptone, 0.5% Bacto Yeast extract, 1 % Sodium Chloride, pH 7.0; autoclaved at liquid cycle for
20 minutes at 15 lb/sq. in.), supplemented with 100 Jlg/ml ampicillin or 20 Jlg/ml kanamycin,
depending on the type of antibiotic resistance selection needed at the time. Cells were stored in
Luria-Bertani medium (LB) with 150/0 glycerol at -20°C.
1. Preparation of Competent Cells
Competent cells were prepared according to Sambrook et al. (1989). A frozen stock of
E.coli cells was streaked on an LB-agar (Luria Bertani medium supplemented with 2% agar;
BioShop) plate, which was inverted and allowed to grow overnight in an oven incubator at 37°C.
A single colony was picked and grown in 5 ml LB for about 5 hours; this was subsequently
inoculate a 500 ml flask of LB. The cells were allowed to grow until reached an OD600 of 0.45
to 0.55 and then harvested by centrifugation (Beckman Avanti™ J-25) at 3,500 rpm, 4°C, for 10
minutes. The c.ell pellet was gently resuspended in 50 ml of transformation buffer (75mM CaCI2,
5 mM Tris Base, pH 7.6; sterilised by filtration through 0.45 micron Gelman Sciences
Acrodisc® filter), left on ice for 16 hours and then collected again by spinning at 3,500 rpm for
10 minutes. The cells were then resuspended in 3 ml of transformation buffer with 150/0 glycerol
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and allowed to sit on ice for 30 to 45 minutes, 150 JlI aliquots were dispensed into Eppendorf
tubes and stored at -80°C until needed.
B. DNA Ligation
T4 recombinant DNA ligase (NEB) was used to perform all DNA ligations. Ligations
were completed in a total volume of 20 JlI at 16°C for 4-16 hours in Ligase buffer (50mM Tris-
HCI, IOmM MgCI2, IOmM DTT, ImM ATP, 50 Jlg/ml BSA; pH 7.8), supplied by NEB. A
typical ligation contained 50-300 ng of digested DNA insert and 50-150 ng of linearized plasmid
DNA, 2 f.ll of ligase buffer, 0.5 JlI of ligase (diluted to 10 unitslf.ll ) and sterile distilled water up
to a final volume of 20 J.ll.
c. Transformation
Competent E. coli were transfonned according to Sambrook el af. (1989). A tube
containing frozen competent cells was placed on ice, after which 10 J.lI of the ligation mixture
was added and then allowed to sit on ice for 30 minutes with occasional shaking. The cells were
shocked by heating at 42°C for 45 seconds and then put back on ice for 2 minutes. Nine
hundred JlI of SOC media (20/0 Bacto-Tryptone (BioShop), 0.50/0 Yeast extract (BioShop), 0.05 0/0
Sodium Chloride, 2.5mM KCI, pH 7.0; autoclaved for 20 minutes at 15 lb/sq. in., liquid cycle;
supplemented with sterile MgCl2 to a final concentration of 10mM and glucose to a final
concentration of 20mM) were added to the cells, which were subsequently incubated at 37°C
with gentle shaking in a bench top shaker (New Brunswick Scientific Gyrotary water bath shaker
G76) for 45 minutes. Following incubation, the cells were spread (100 JlI per plate) on LB-agar
plates supplemented with either ampicillin or kanamycin. The cells were allowed to grow for 16
hours at 37°C into individual colonies" which were picked for plasmid extraction and analysis.
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D. Plasmid DNA Isolation
1. Small Scale DNA Isolation
The small-scale purification of plasmid DNA was carried out according to Sambrook el
al. (1989). Single colonies were picked, using autoclaved wooden applicator sticks
(Fisherbrand®), from the LB-agar plates and transferred to a glass test tube containing 2 ml LB
(supplemented with the appropirate antibiotic for selection). The tubes were then transferred to
the bench top shaker and incubated at 37°C with shaking for 16 hours. The cells were harvested
by transferring the culture to autoclaved Eppendorf tubes which were then centrifuged at 12,000
rpm for 30 seconds (Sorval® MC12V). The supernatant was decanted from the tubes and 100 JlI
of lysozyme solution (1 OmM ethylenediamine tetraacetic acid [EDTA], 50mM glucose, 125 mM
Tris-HCI, pH 8.0; sterilised by filtration) was added to the cell pellet. The tubes were vortexed
(American Hospital Supply Corporation Deluxe Mixer) until the cell pellet was completely
resuspended. The solution was then allowed to incubate at room temperature for 10 minutes
before 200 Jll of alkaline SDS (1 % SDS~ 200mM NaOH) was added. The solution was mixed
gently~ allowed to sit at room temperature until the solution cleared and then 150 JlI of sodium
acetate (3M; pH 4.8) was added. The solution was mixed, incubated on ice for 20 minutes and
then centrifuged for 5 minutes at 12,000 rpm. The supernatant was transferred to new autoclaved
Eppendorf tubes and 900 JlI of cold 95% ethanol was added to each. The solution was mixed and
then centrifuged for 5 minutes at 12,000 rpm. The supernatant was decanted and the DNA pellet
that precipitated was washed with 200 JlI of 70% ethanol, air dried for 10 minutes and then
resuspended in either 100 JlI of TE buffer (100 mM Tris, 1mM EDTA; pH 7.5; Sterilised by
autocla\'ing) or sterile distilled water.
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2. Large Scale DNA Isolation
The appropriate transformed E. coli culture was used to inoculate a 500 ml LB flask,
supplemented with antibiotics. The culture was allowed to shake overnight at 37°C in the bench
top incubator.
a) Cesium Chloride Gradient
The cesium chloride gradient method of plasmid DNA purification was performed
according to Sambrook et ale (1989). Initially, the cells were harvested by transferring the
culture to autoclaved bottles (250 ml Sepcor® Polypropylene centrifuge bottles) and then
centrifuging (Beckman Avanti® J-25 centrifuge) at 8,000 rpm for 8 minutes. The supernatant
was decanted from the bottles and the cell pellet was completely resuspended by vortexing in 10
ml of lysozyme solution. The solution was then allowed to incubate on ice for 15 minutes before
20 ml of alkaline SDS was added. The solution was mixed gently, allowed to incubate at room
temperature for 10 minutes and then 15 ml of sodium acetate (3M; pH 4.8) was added. The
solution was mixed gently, incubated on ice for 30 minutes and then centrifuged for 15 minutes
at 10,000 rpm. The supernatant was then transferred to a new autoclaved centrifuge bottle and
90 ml of cold 950/0 ethanol were added to it. The solution \\!as mixed, allowed to incubate at -
20°C for 20 minutes and then centrifuged for 15 minutes at 10,000 rpm. The DNA pellet was
resuspended in 5 ml of autoclaved water before 10 ml of cold 95% ethanol was added. The
solution was then incubated at -20oe for 10 minutes before it was centrifuged again at 10,000
rpm for 15 minutes. The final pellet was air dried for 10 minutes before being resuspended in 2
ml of sterile distilled water.
Subsequently, 150 JlI of ethidium bromide (10 mg/ml) was added and the density of the
solution was brought up to 1.55 to 1.59 g/ml by adding the appropriate amount of cesium
chloride (CALEDON). The solution was transferred to Beckman Quick-Seal® centrifuge tubes
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and sealed by heating. The samples were centrifuged (Beckman TL-I 00 ultracentrifuge) for 20
hours at 60,000 rpm and 22°C. Following centrifugation, two prominent red bands could be
visualised. The lower band was extracted using a hypodermic syringe attached to a needle and
transferred to a sterile Eppendorf tube. The DNA was washed several times with water-saturated
isoamyl alcohol until the solution was no longer pink in colour. Subsequently, two volumes of
sterile water were added and the DNA was ethanol-precipitated, centrifuged at 10,000 rpm for 10
minutes, air dried, and resuspended in a suitable amount of TE buffer or sterile water.
(1) DNA Dialysis
DNA samples purified using the cesium chloride gradient technique were dialysed before
they were used for mammalian cell culture transfection. A 5-centimetre piece of SpectralPor® 3
(Spectrum Medical Industries, Inc.) membrane tubing was first autoclaved, at 20 lb./sp.in. for 10
minutes on liquid cycle, immersed in water, and allowed to cool before it was used. The DNA
solution was transferred to the tubing which was then placed in two litres of TE buffer. The
solution was dialysed for several hours, before fresh TE buffer was added and dialysis continued
overnight.
b) Maxi-prep Wizard Kit
DNA was purified using the Wizard™ plus Maxipreps DNA Purification System
(Promega®) according to the manufacturer's instructions. A previously grown 500 ml cell
culture was transferred to sterile 250 ml centrifuge bottles and centrifuged for 10 minutes at
8,000 rpm and 4°C. The cell pellet was resuspended in Cell Resuspension Solution (50 roM
Tris-HCl, 10mM EDTA, 100 Jlglml RNase A; pH 7.5). The cell pellet was completely
resuspended by vortexing. Afterward, 15 ml of cell lysis solution (0.2M NaOH, 1% SDS) was
added and mixed by inversion until the solution turned clear (20 minutes). Subsequently, 15 ml
of neutralisation solution (I.32M potassium acetate, pH 4.8) was added and the solution was
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again mixed by inversion. The solution was then centrifuged for 15 minutes at 10,000 rpm and
22°C. The clear supernatant was passed through sterile filter paper (Whatmans® # 1). Once the
supernatant was filtered, 20 ml isopropanol was added and the solution was mixed well before
centrifugation for 15 minutes at 10,000 rpm and 22°C. Following centrifugation, the supernatant
was discarded, after which the DNA pellet was dried at room temperature and resuspended in 2
ml of TE buffer. The resuspended DNA was then mixed with 10 ml of Wizard® maxipreps
DNA purification resin and transferred to a Wizard® Maxicolumn, which was attached to a
vacuum manifold port. Once the excess liquid was removed from the column, 25 ml of Column
Wash Solution (80 mM potassium acetate, 8.3 mM Tris-Hel, 40 IlM EDTA, pH7.5, 55%
ethanol) was added. A subsequent wash was done with 5 ml of 80% ethanol. The column was
allowed to dry for 5 minutes before the DNA was eluted in 2 ml of preheated (65°C to 70°C)
water. This was accomplished by spinning the column in a 50cc screw-cap centrifuge tube at
2,500 rpm for 5 minutes. The eluted DNA was passed through a 0.2 micron Luer-Lok® filter
before storage at 4°C.
E. DNA and RNA Concentration Determination
The purity of DNA or RNA was determined by measuring the absorbance of the sample
at 260 nm and 280 nm (Hitachi U-2000 Spectrophotometer). An OD26ol0D28o of 1.8 to 2.0
indicated a pure preparation.
The DNA concentration was detennined by measuring the absorbance at 260nm and
applying the following formula: [DNA]=(A26o x Dilution factor x 50)/1000 Jlg11l1. For the
determination of RNA concentration, the following equation was applied: [RNA]=(A26o x
Dilution factor x 40)/1000 Jlg/JlI.
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F. Restriction Enzyme Digestion
Restriction enzymes were used according to the manufacturer's (NEB) recommendations.
A typical digestion contained about 2Jlg of DNA, 2JlI of lOx NEBuffer (supplied by the
manufacturer) supplemented with lOOllg/ml BSA (if specified by the manufacturer, depending on
the restriction enzyme used), 2 to 5 units of restriction enzyme, and sterile distilled water to a
final volume of 20 Jll. The digestion was allowed to incubate in an oven incubator at 37°C for 4
to 8 hours before the samples were analysed by gel electrophoresis.
G. CIP/SAP Treatment of DNA
1. Calf Intestinal Phosphatase (CIP)
CIP was used according to the manufacturer'ls (NEB) recommendations. A
dephosphorylation reaction with CIP typically contained 1 to 5Jlg of vector DNA, O.2JlI (1 unit)
of CIP, 2 JlI of supplied CIP buffer (50mM NaCI, IOmM Tris-HCI, 10mM MgCI2, ImM
Dithiothreitol, pH 7.9) and sterile distilled water to a final volume of 20 Jll. The reaction was
incubated at 37°C for one hour before the DNA was phenol extracted and ethanol precipitated.
2. Shrimp Alkaline Phosphatase (SAP)
The shrilnp alkaline phosphatase was used according to the manufacturer's
recommendations (Boehringer Mannheim®). About 50 ng of linearized vector DNA were mixed
with 2 JlI of the SAP buffer provided (500mM Tris-HCI, SOmM MgC12, pH 8.5), 1 JlI of SAP
(1 unitlJlI) and sterile distilled water to a final volume of 20 Jll. The reaction was incubated at
37°C for 10 minutes, after which the enzyme was inactivated at 6SoC for IS minutes.
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H. Klenow Treatment ofDNA
Klenow Fragment (NEB) is a proteolytic product of DNA Polymerase I. Klenow retains
the polymerase activity, but it has lost 3'~5' and 5'~3' exonuclease activity through mutation
and proteolytic cleavage respectively. KIenow was used according to the manufacturer ~ s
recommendations. In fill-in experiments, 1 Jlg of DNA was mixed with 2 JlI of the supplied
Klenow (10 units) buffer (IOOmM Tris-HCI (pH 7.5), 50mM MgCI2, 75 mM dithiothreitol), 33
J,1M of deoxynucleotide triphosphate (dNTP) and 1 unit of Klenow (5 units/~l). The reaction
mixture was incubated at 2SoC for 15 minutes, phenol extracted, and ethanol precipitated.
I. Polymerase Chain Reaction (peR)
Primers used in PCR (Saiki et al. 1985; Mullis et al. 1986) experiments were designed
using VECTOR NTI 4.0 software (InforMax) and synthesised by Procyon Biopharma Inc.
(London, ON.). The primers were designed to be 20 to 26 nucleotides in length, possess a G/C
content of more than 500/0, and a have a melting temperature of 58°C to 65°C. PCR reactions
typically contained 10 to SOng of template DNA, 50 to 250 JlM of dNTP mix ( equal amounts of
dATP, dTTP, dGTP and dCTP), 10 to 100 JlM of forward and reverse primer, 0.25 to 2.5 mM
MgC12, 0.2 JlI of Taq Polymerase (MBI Fermentas; 5 units/J,1I), 5 JlI of supplied Taq buffer
(lOOmM Tris-HCl (pH 8.8), 500 mM KCI and 0.8% nonidet P40) and sterile, distilled water up
to a final volume of 50 Jll. The reactions were run in a SingleBlock™ System (EasyCycler™
Series, ERICOMP INC.). The samples were initially deantured for 3 minutes at 94°C. The
template was amplified in 32 peR cycles consisting of the following: denaturation (1 minute at
94°C), primer annealing ( 2 minutes at 55°C) and primer extension (3 minutes at 70°C).
Afterward, a final primer extension was done at 70°C for 10 minutes.
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J. Purification of DNA Fragments
1. GeneClean®
GeneClean® (BID 101 Inc.) was used to purify DNA fragments from agarose gels,
according to the manufacturer's recommendations. Generally, the desired DNA band from a
previously run gel was observed under a UV transilluminator, excised, transferred to an
Eppendorf tube, and weighed. A volume of 3 M NaI equal to three times the weight of the
agarose band was added to the tube. The agarose was then allowed to dissolve at 55°C before 5
JlI of GlassMilk® was added, mixed and allowed to incubate at room temperature for 5 minutes.
The sample was then centrifuged at 12,000 rpm for 5 seconds and the supernatant was decanted.
The GlassMilk® pellet was washed three times with New Wash (provided by the manufacturer,
stored at -20°C). The pellet was allowed to dry before its resuspension in 30JlI of sterile distilled
water. The sample was incubated at 55°C for 3 minutes in order to elute the DNA, and then
centrifuged at 12,000 rpm. The supernatant \vas collected and stored at 4°C for future work.
2. Phenol:chloroform Extraction
Phenol:chloroform extraction was used to remove proteins from DNA samples. The
phenol :chloroform mixture contained 25 :24: 1 of phenol :chloroform:isoamyl alcohol respectively
(stored at 4°C). ·The mixture was equilibrated to a pH of 7.8 to 8.0 using Tris Hel (pH 8.0). An
equal volume of phenoI:chloroform mixture was added to the sample, mixed by inversion several
times, and centrifuged at 13,000 rpm for 5 minutes. The upper layer was transferred to a fresh
tube and 3M sodium acetate, pH 7.5, (10% of the sample volume) was added. The DNA was
then ethanol precipitated, air dried and resuspended in a suitable volume of sterile water or TE
buffer. The DNA was stored at 4°C.
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K. Gel Electrophoresis and Documentation
Agarose gels were made using 0.6 to 1% w/v agarose in TAE buffer (40 mM Tris base,
10mM sodium acetate, 1.8 mM EDTA; pH adjusted to 7.8 using glacial acetic acid). The
mixture was heated to boiling before it was allowed to cool to 50°C. Ethidium bromide was
added to a concentration of 0.25Jlg/ml. The mixture was then poured into a polycarbonate cast to
solidify. The gel was then transferred to an electrophoresis box and TAE buffer was used as the
running buffer.
Typically, 18 JlI of digested DNA was mixed with 3 JlI of loading buffer (50% sucrose,
10mM EDTA, 1% SDS, 0.1 % bromophenol blue; filtered through #1 Whatman® paper) prior to
loading into the pre-cast gel. A lambda DNA marker (lambda HindIII digest; NEB) was used to
estimate the size of the sample DNA bands. The samples were electrophoresed at 5 to 10
volts/em using a BIORADTM 200/2.0 power supply. Subsequently, the bands were observed
under a UV transilluminator box (Fisher Scientific® 312 nm variable intensity transilluminator
FBTIV-614) and photographed using the Snappy® program (Play Incorporated™) via a video
camera.
L. Mammalian Cell Lines
MDBK cells (Bovine Kidney, S. Madin and N.B. Darby; ATCC Number: eCL-22) and
their derivative M5 cells were the main cell lines used for viral growth, plaque assays, and
transfections. The following cell lines were also used and tested for permissivity to BAV2 and
efficiency of DNA uptake: Bu (IMR-31 Buffalo lung, S.B. Dwight; ATCC Number: CCL 40),
EBTr (Embryonic bovine trachea, A.J. Kniazeff, W.A. Nelson-Rees and N.B. Darby; ATCC
Number: eCL 44)~ BT (Bovine turbinate~ A.W. McClurkin; ATCC Number: CRL 1390), BIn
(Bovine lymph node, ATCe Number: CRL 6017), FB2.K (Bovine Kidney, ATeC Number:
CRL 6033), FB5.Bm (Fetal bovine bone marrow, ATCC Number: CRL 6043), FB5.Ln (Fetal
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bovine lymph node, ATCC Number: CRL 6044), LB9.K (Bovine Kidney, ATCC Number: CRL
6055), LB10.K (Bovine Kidney, ATCC Number: CRL 6061) and SJMRF (Buffalo, ATCC
Number: CRL 6072).
Cells were grown as described in Burleson et af. (1992), in 2 to 20ml Minimum Essential
Medium (MEM) supplemented with 2mM L-Alynyl-L-Glutarnine (Gibco BRL supplied in
0.85%NaCI), 0.225% w/v sodium bicarbonate, 100/0 donor or horse serum, and 1% antibiotic
(contains 10,000 units/ml of penicillin, 10,000 Jlg/ml of streptomycin, 25 ~g/ml of amphotericin
B in 0.85% NaCI).
Cells were grown to 80% to 90% confluency before they were passaged at a ratio of 1:4.
The cell monolayer was initially washed with 1 to 5 ml of versene (O.53mM EDTA, 0.137M
NaCl, 2.7mM KCI, 3.2mM Na2HP04 , 1.lmM glucose, 1.47mM KH2P04; sterilised by
autoclaving for 15 minutes at 15 lb/sq .in. on liquid cycle) prior to incubation in 1 to 10 ml
versene and 0.25 to 2 ml trypsin (2.5g/L trypsin and 0.85 gIL NaCl; Gibco BRL) at 37°C. The
cells were allo\ved to lift off the plate for 5 minutes before they were transferred to a 50cc tube
and centrifuged at 1,500 rpm for 10 minutes. The cells were then resuspended in growth
medium, and transferred to appropriately sized plates before they were returned to the CO2
incubator (Fisher Scientific IsoTemp® incubator; Model 546). The cell culture plates (35mm
plate surface area: 962mm2; lOOmm plate surface area: 7,854mm2; 150mm pate surface area:
17,671mm2) were normally seeded at a density of 300 cells/mm2• The incubator was kept humid
by placing a bowl of sterile water inside. The CO2 level was kept at 5% and the temperature was
maintained at 37°C.
M. Fetal Calf Primary Cell Culture
Fetal bovine lung and kidney tissues were obtained from a deceased pregnant cow
(Kingma Meat Products Ltd., Wellandport, Ontario). The tissues were rinsed with PBS buffer,
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dissected into 1 cm3 fragments and treated with trypsin for one hour at room temperature.
Afterwards, the resulting mixture was filtered through sterile cheese cloth (Sigma), centrifuged
for 10 minutes at 1000 rpm and 22°C. The cell pellet was resuspended in growth medium, as
described in the previous section, and cultured in 60 mm cell culture plates. The plates were
placed in a C02 incubator at 37°C and the media was replaced every three days.
N. Mammalian Cell Lines Frozen Stocks
Cells from confluent plates were lifted off the plate using versene and trypsin, centrifuged
for 10 minutes at 1,500 rpm and 4°C, and resuspended in donor serum that was supplemented
with 100/0 dimethyl sulfoxide (DMSO). Aftenvards, cells were transferred to 2 ml tubes and kept
at -80°C for 16 hours before they were transferred to a liquid nitrogen cryogenic tank for storage.
o. Cell Line Transfections
In this study" two different transfection techniques, calcium phosphate and lipofectamine®
transfection, were used to assess DNA uptake, attempt to rescue a mutant or establish a cell line.
1. Calcium Phosphate
The calcium phosphate transfection prodedure was performed according to Graham et a1.
(1973). Preceding transfection, cells were subcultured the night before and plated at 300
ceII/mm2 (300,000 cells in a 35 mm plate); fresh media was added the following morning. To
each 35 mm plate, 5 Ilg of plasmid DNA was mixed in TE buffer (pH 8.0, filter sterilised) to a
final volume of 75 III with 25 III of2.5 M CaCl2 (filter sterilised). The DNA-CaCI2 mixture was
slowly added to 100 III of 2x Hepes-buffered saline solution (280 mM NaCI, 10 mM KCI, 1.5
mM Na2HP04.2H20, 12 mM dextrose, 50 mM HEPES; filter sterilised). The solution was
allowed to incubate at room temperature for 30 minutes to allow for the formation of calcium
phosphate-DNA precipitate. Subsequently, the mixture was added to the cells and allowed to
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incubate in a CO2 incubator at 37°C. The media was replaced after 3 to 5 hours. The cells were
permitted to grow for 24 to 48 hours post-transfection, and depending on the experiment, were
subjected to selection for antibiotic resistance, stained for lacZ activity, or tested for viral growth.
2. LIPOFECTAMINETM
LIPOFECTAMINETM (Gibco BRL®) reagent is a 3:1 (w/w) liposome mixture of 2,3-
dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium trifluoroacetate
(DOSPA) (Chemical Abstracts Registry name: N- [2- (2,5- bis[(3- aminopropyl)amino]- 1-
oxpentyl}amino)ethyl] -N,N- dimethyl- 2,3- bis (9- octadecenyloxy)- 1- propanaminium
trifluoroacetate), the polycationic lipid, and dioleoyl phosphatidylethanolamine (DOPE), the
neutral lipid, in water. It is suitable for the transfection of DNA into cultured eukaryotic cells.
a) Transfection Optimisation
The optimal transfection protocol was determined by interpretation of the results in this
thesis using the plasmid pCMVp, a plasmid containing the E.coli lacZ gene under the control of
the human cytomegalo virus (CMV) promoter. In a 35mm tissue culture plate, approximately 3
x 105 cells were seeded in 2ml of gro\\1:h medium supplemented with serum and antibiotics. The
cells were then incubated in a CO2 incubator at 37°C until the cells were 50% to 60% confluent
For each transfection, the DNA (0.1, 0.2, 0.4, 0.6, 0.8, 1.6, 3.2 Jlg) were diluted into
100JlI serum-free MEM medium. In another tube, 2.5J.lI of Lipofectamine™ reagent was diluted
into 1OOJ.lI serum-free MEM medium. The two soh.itions were combined, mixed gently, and
incubated at room temperature for 30 minutes. Meanwhile, the cells were washed with 1 ml of
serum-free medium and then covered with 2 ml of serum-free medium. The lipid-DNA
complexes were added onto the washed cell monolayer.
The cells were incubated for 4 hours in a CO2 incubator at 37°C; following the removal of
the transfection mixture, 2 ml of growth medium containing 12% serum and 1% antibiotic was
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added. Cells were stained for lacZ activity 24 to 48 hours post-transfection. The optimum
conditions for transfection were observed when the following procedure was used: 0.4 Jlg of
plasmid DNA and 2.5 JlI of lipofectamine® with a cell incubation time of 4 to 6 hours.
This procedure was also used to transfect DNA for stable expression and establishment of
cell lines. When the plasmid pCMV-EI-neo was used, the cultures were not stained post-
transfection. Althematively, cells were passaged at a ratio of 1: 10 into growth medium
containing Geneticin (GibcoBRL®), selective for the reporter neo gene.
3. LIPOFECTAMINE PLUS ™
The Lipofectamine Plus™ tranfections were performed according to the manufacturer's
recommendations and carried out in the same manner as the normal Lipofectamine™
transfection, described in the previous section. The only modification was the addition of 3 J.lI of
PLUS reagent (for 35 mm cell culture plates) to the plasmid DNA prior to mixing the DNA with
the LipofectamineTM.
4. FuGENE ™
FuGene ™ (Beohringer Mannheim®) reagent is an exclusive blend of non-liposomal
lipids and other compounds in 800/0 ethanol. The manufacturer promises minimal cytotoxicity
for eukaryotic cells and that transfections can be performed in the presence of a normal serum
concentration.
Prior to transfection, 3 x 105 cells were seeded in a 35mm plate with 2 ml of growth
medium. The following day, 4 JlI of FuGENE ™ reagent were added to IOOJlI of serum-free
medium. The mixture was allowed to sit at room temperature for 5 minutes, after which the
diluted FuGENE ™ reagent was added drop-wise to another tube containing 1 Jlg of plasmid
DNA. The FuGENE ™ -DNA complex was allowed to form by incubating at room temperature
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for 15 minutes. Following incubation, the transfection mixture was added drop-wise to the cells,
which were already covered with 2 ml of growth medium, ensuring even dispersal. The cells
were incubated in a C02 incubator at 37°C for 24 hours before they were stained for lacZ
activity.
5. Electroporation
Electroporation (Newmann et aI., 1982) is the application of brief, high-voltage electrical
pulses which cause the formation of small (nanometers in diameter) pores in the cell membrane.
Subsequently, the DNA can be directly picked up through these pores into the cytoplasm and
then into the nucleus for expression.
A confluent 100 mm plate (8.5 x 106 cells) was used per transfection. The cells were
lifted off the plate with trypsin and verscene, washed with phosphate-buffered saline solution
(PBS; 140mM NaCI, 2.6mM KCI, 4mM Na2HP04, and 1.5mM KH2P04, pH 7.4 , sterilised by
autoclaving), resuspended in 0.5 ml of PBS and then kept on ice until they were ready to be
electroporated. Cells were then mixed with a final DNA concentration of 1 to 40 Jlg/ml and
electroporated at 700 v/cm, 1000n and 25JlFD using the Gene Pulser® II (BIO-RAD) and the
Gene Pulser® cuvettes (0.4 em electrode). Typically, 500/0 to 800/0 of the electroporated cells are
destroyed in the process. Therefore, the cells were diluted 1: 10 with growth medium and plated
in two 24-well plates. The cells were allowed to recover for 24 hours before antibiotic selection
was applied.
P. Selection with Geneticin@
Cultured mammalian cell lines differ widely in their sensitivity to Geneticin (G418;
Gibeo BRL). The appropriate concentration used for selecting stably, transfeeted cells had to be
determined experimentally. Twenty four to 48 hours following transfection, new medium
containing 0418 was added to the cells to select for those expressing the neomycin resistance.
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Non-transfected cells from different cell lines were tested for resistance to the antibiotic. The
concentration of Geneticin® (50 to 100 Jlg/ml) that was shown to have an effect on the non-
transfected cells was sustained in further experiments to select for stably transfected cells. Fresh
growth medium containing the antibiotic was added to the plates every 2 to 3 days until most of
the cells had been killed, after which time the concentration of Geneticin® was decreased to 25 to
75 Jlg/ml. The cells were surveyed under antibiotic selection until they were confirmed to
express the El region ofBAV2.
Q. Isolation of Single Focus
During selection with the antibiotic G418, several foci were observed to be continuously
growing. A single focus were isolated in one of two ways: (I) by lifting up the cells, diluting
them 1: 10 and plating them in a 24-well plate at a concentration of 1 cell/plate or (2) by using
autoclaved aluminium rings to isolate the foci from the rest of the plate, lifting up the cells frqrn
inside the ring and then transferring these cells to another plate.
R. Mammalian Cell Counter Staining
Man1malian cells were grown on glass slides for 24 hours and then fixed using formalin
fixation buffer (150 mM NaCI, 5% formaldehyde; pH 7.4) at 4°C for 24 hours. The cells were
then rinsed with distilled water and dehydraded through graded ethanol solutions (500/0, 70%,
95% and 100%) for 1 minute each. Slides were then washed in xylene for 1 minute, and air dried
for 15 minutes.
Afterwards, the cells were stained with hematoxylin (Sigma) for 30 minutes, washed in
O.IX sse for 1 minute, and then in 2X sse (0.3 M NaCI and 0.03 M Na3C6Hs07.2H20) for 15
minutes. The slides were then treated with another cycle of successive ethanol washes, as before.
Subsequently, the cells were stained with eosin (Sigma) for 30 minutes and then washed in 950/0
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and 100% ethanol for 3 minutes each. The slides were later soaked in xylene for 20 minutes and
mounted in 50% glycerol.
s. Histochemical Assay for lacZ Activity
Cells previously transfected with the plasmid carrying the lacZ reporter gene were stained
for lacZ activity. The cells were washed with PBS and then fixed with 1 mI of 4%
paraformaIdehyde (4% parafomaIdehyde in PBS; the solution was heated and the pH was
adjusted to 10 to allow the parafonnaldehyde to dissolve; the solution was cooled to room
temperature and the pH was adjusted to 7.2). The cells were incubated at room temperature for 5
minutes, after which the solution was aspirated and the cells were washed three times with PBS.
Afterward, the staining solution, lmg/ml x-gal (5-bromo-4-chloro-3-indolyl-P-o-
galactopyranoside; stock of 20 mg/ml in dimethylfonnamide, stored at -20°C; Sigma) diluted in
the mixer (100mM sodium phosphate (pH 7.3), 3mM K3Fe(CN)6, 3mM ~Fe(CN)6. 1.3mM
MgCI2; pH7.4), was added. The cells were incubated in a CO2 incubator at 37°C for 16 hours
before blue cells were counted for statistical analysis.
T. Viral Strain Propagation
BAV2, strain 19 (ATCC VR-314), was propagated in MDBK cells according to the
procedure described in Burlesson et al. (1992). Sixteen hours after the cells were passaged, they
were washed with PBS2+ (PBS supplemented with ImM CaCl2 and 0.5mM MgCI2) and the virus
was added at a concentration of 1 moi (multiplicity of infection). The cells were incubated in a
C02 incubator at 37°C for one hour, the unattached virus was aspirated, and growth medium
containing 6% serum and antibiotics was added to the plates. ePE (cytopathic effect) normally
appeared in four days, after which the cells and the media were harvested and transferred to a 50
cc tube. Subsequently, the media were centrifuged for 10 minutes at 4,500 rpm and 4°C. The
supernatant was transferred to fresh tubes and stored at 4°C. The cells were resuspended in PBS
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and put through three freeze-thaw cycles, using liquid nitrogen and a 37°C water bath.
Afterwards, DMSO (10% final concentration) was added before the samples were stored at -
u. Hirts Extraction
The procedure of Rirts extraction was perfonned as modified by Haj-Ahmad and Graham
(1986). Typically, the Ad particles were first resuspended in TE buffer and mixed in equal
volume with 2x lysing buffer (20mM EDTA, 20 mM Tris HCl, 1% SDS; pH 8.0), supplemented
with 1mg/ml pronase (20mg/ml stock in 10mM Tris Hel, 10mM NaCI, pH 7.5; stored at -20°C;
Boehringer Mannheim). The mixture was incubated in an oven incubator at 37°C for 16 hours,
after which it was extracted with phenol/chloroform/isoamyl alcohol and then centrifuged at
8,000 rpm for 10 minutes. The upper aqueous layer was measured using a graduated cylinder
and transferred to a fresh tube. A volume of 3 M sodium acetate, equal to one tenth the volume
of the aqueous layer, was added. After mixing, 950/0 cold ethanol, equal to twice the total volume
of the solution, was added to the tube. The solution was mixed and centrifuged for 15 minutes at
10,000 rpm and 4°C. The DNA pellet was washed with cold 700/0 ethanol and allowed to dry at
room temperature. The DNA was resuspended in an appropriate volume of sterile water or TE
buffer depending on the amount of viral DNA recovered.
v. Plaque Assay
The plaque assay technique (described in Burlesson et al.,1992) was used to determine
the number of infectious particles in a purified stock of Ad. Generally, MDBK cells were plated
in 35 mm 6-well plates at a concentration of 300 cell/mm2 (300,000 cells in a 35 mm plate).
The cells were allowed to grow for 16 hours in a CO2 incubator at 37°C, after which the medium
was vacuum aspirated and the cells were washed in PBS2+. Meanwhile, ten fold dilutions (10-1 to
10-9) of the virus stock being tested were made in PBS2+. One hundred JlI of each dilution was
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added to duplicate plates after which the cells were incubated in a C02 incubator at 37°C for one
hour to allow the virus to adsorb to the cell membrane. Subsequently, the unbound virus was
vacuum aspirated and the cells were covered with 3 ml of the overlay mix (2 x MEM
supplemented with 24 mM MgC12 and 4% serum, mixed with an equal volume of melted ] .2%
noble agar). Following solidification of the overlay mix, the plates were transferred and
maintained in a CO2 incubator at 37°C until plaques could be observed. The cells were then
fixed with 100/0 formalin for 30 minutes prior to the removal of the overlay agar layer. The cells
were washed with PBS and stained with 2 ml of 1% crystal violet by incubating at room
temperature for 30 minutes. Aftenvards, once the staining solution was removed, the plaques
were counted. The virus dilution that resulted in observable and distinct plaques was used to
estimate the number of pfus (plaque forming units). To estimate this value, the number of
plaques counted was multiplied by the dilution factor and the reciprocal value of the volume
used. The number of pfu was reported as a concentration of pfu/mI.
w. Southern Hybridization
Localising specific sequences of DNA was accomplished using a modification of the
Southern technique (Southern, 1975). About 10Jlg of genomic DNA was digested with the
desired restriction enzyme and the bands were separated by 0.7% agarose gel electrophoresis.
1. Transfer of DNA
After electrophoresis, the unused parts of the gel were trimmed and the DNA was
denatured by soaking the gel fragment in 200 ml of denaturation solution (1.5 M NaCI and 0.5 M
NaOH) for 45 minutes. The gel was then rinsed with distilled water and soaked in neutralisation
solution (1 M Tris, 1.5 M NaCI; pH 7.4). The neutralisation solution was replaced with fresh
solution and the gel fragment soaked again for 15 minutes.
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A pyrex tray with a sponge block was filled with 10 x SSC (1.5 M NaCI and 0.15 M
Na3C6Hs07.2H20) until the sponge appeared completely wet and saturated with the solution.
The sponge was then covered with two pieces of 3MM® Whatman paper, eliminating any air
bubbles trapped between the sponge and the Whatman paper. The gel was placed on top of the
Whatrnan paper. Cling Wrap was used to cover the exposed parts of the sponge in order to direct
the flow of the solution through the gel.
A piece of nylon membrane (GeneScreen Plus®, DuPont™), the size of the gel, was
wetted with sterile distilled water and then soaked in 10 x SSC for 5 minutes. Once completely
soaked, the membrane was placed on top of the gel and a glass rod was used to eliminate any
trapped air bubbles. The membrane was then covered with a piece of Whatman paper and topped
with a 10-cm thick stack of paper towelling. The paper towelling was weighed down with a 500
g weight. Transfer of DNA was allowed to proceed for 16 hours after which the membrane was
soaked in 6x sse for 5 minutes, dried at room temperature, and then cross linked using UV
Stratalinker™ 1800 (Stratagene®) for I minute. The membrane was then transferred to a
hybridization cylinder for labelling.
2. Radiolabelling of DNA Probe
DNA probes were labelled using the Nick Translation System (Promega®). The kit is
supplied with: (I) DNase I, which creates nicks within the DNA double strand and (2) DNA
Polymerase I, which adds a new residue while the 5'-t3' exonuclease activity of this enzyme
removes the old residue at the 5' end of the nick.
A typical nick translation reaction contained 10 JlI of nucleotide mix (100JlM GTP, TTP,
erp), 5 JlI of lOx Nick Translation buffer (500mM Tris-HCl, 100 rnM MgS04, lrnM DTT; pH
7.2),1 Jlg of DNA, 7 JlI [a-32P]dATP (70Jl Ci at 400 Ci/mrnole and IOmCi/ml), and 5 JlI of DNA
Polyrnerase/DNase I mix (IJlg/JlI DNA Polymerase, O.2ng/JlI DNase I, 50% glycerol, 50mM
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Tris-Hel, IOmM MgS04, O.lmM DTT and 0.5 Jlg/JlI BSA). The reaction was incubated for 1
hour at 15°C, after which 5 J.11 of stop solution (0.25M EDTA; pH 8.0) was added.
3. Prehybridization, Hybridization and Washing
Prehybridization and hybridization were carried out at 65°C in a Hybaid hybridisation
oven (Hybaid® micro-4). The membrane was prehybridized at 65°C for 30 minutes in 10 ml of
hybridization solution (1 % SDS, 1M NaCI, 10% dextran sulfate supplemented with 100 Jlg of
salmon sperm DNA). Hybridization was done in 30 ml of hybridization solution (supplemented
with 100 Jlg of salmon sperm DNA and 50 JlI of the radiolabelled probe; boiled for 5 minutes
and cooled to 65°e before use) at 65°e for 16 hours. Subsequently the membrane was washed in
100 ml of 2 x sse for 10 minutes at room temperature, then in 2 x sse (supplemented with
0.1 % SDS) for 1 hour at 65°C, and finally in 0.1 x SSC for 10 minutes at room temperature.
4. Film exposure and developing
Follo~'ing hybridization, the membrane was completely dried at room temperature,
placed between Cling Wrap and a sheet of Whatman paper (underneath) and placed in an X-ray
cassette containing a BioMax film (Kodak®, Scientific Imaging Systems). The film was exposed
for 1 to 16 hours at -80°C or room temperature, depending on the amount of radioactivity present
on the membrane; it was then developed and fixed using a Kodak GBX developer and Kodak
GBX fixer. The film was finally rinsed with distilled water and dried at room temperature.
x. Trizol@ Extraction of Total RNA
TRIZOL®LS Reagent (Life Technologies™), a mono-phasic solution of phenol and
guanidine isothiocyanate, was used to isolate total cellular RNA. After removing the gro~1h
medium, the cells in a 150mm cell culture plate were covered with 5 ml of TRIZOL®LS reagent.
The reagent was then used to wash the cells off of the plate. Following the complete mixing of
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the cells with the reagent, the mixture was allowed to incubate at room temperature for 5
minutes. Subsequently, the mixture was extracted using 1 ml of chloroform for 2 to 3 minutes
followed by a 15 minute-centrifugation at 10,000 rpm and 4°C. The resulting upper phase was
transferred to a new tube and mixed with 2.5 ml of isopropanol and then centrifuged at 10,000
rpm and 4°C for 15 minutes. The RNA pellet was washed once with 5 ml of 75% ethanol and
centrifuged for 5 minutes at 10,000 rpm and 4°C. The RNA pellet was air dried and resuspended
in Iml of RNase-free water (0.1 % diethyl pyrocarbonate, incubated overnight in an oven
incubator at 37°e then autoclaved for 15 minutes in liquid cycle) by incubating in a water bath at
55°C to 60°C for 10 to 15 minutes. The integrity of the purified RNA was checked by analysis
using 0.90/0 agarose gel electrophoresis.
Y. Northern Hybridization
Thirty ~g of isolated RNA were mixed with 5 ~l of RNA loading buffer and heated to
65°C for 20 mins prior to separating the sample by agarose gel electrophoresis (1 % agarose in 0.1
M phosphate buffer, pH 6.8). The RNA was separated by electrophoresis for 4 to 6 hours at 1
v/cm using a phosphate running buffer. Following electrophoresis, the integrity of the RNA was
detennined under UV light. The RNA was then transferred to a nylon membrane (as described
for the Southern hybridisation) without pre-treatment of the gel. Prehybridisation, hybridisation
and film exposure were carried out as previously described.
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IX. Results
The strategy used for developing a packaging cell line for recombinant BAV2 was
patterned, with modifications, after the packaging cells used for human Ad vectors. In that
system, the 293 packaging cell line, which consitutively expresses AdS E 1 products, not only
complemented the missing El functions in the vector intentionally removed to accommodate the
size of the foreign gene insert, but also served as the standard cells for contransfection to
generate other recombinant Ad regardless of the presence of El in the vector (Raj-Ahmad and
Graham, 1986). However, since recombinant AdS generated through the 293 packaging cell line
often co-purified with wild-type revertants, the subsequent strategy for a BAV2 packaging cell
line was modified to avoid generating unwanted wild-type revertants.
The desired BAV2 packaging cell line was designed to incorporate the following
properties: 1) The cell line must minimize or prevent the generation of revertants; 2) the cell
line must be readily transfected; 3) the gene or genes for complementing missing viral functions
must be stably integrated in the cellular genome and constitutively expressed at levels
appropriate for packaging viral particles; and 4) the packaging cell line must support routine
propagation of the recombinants in expanded scales.
To achieve these objectives, we focused on developing a cell line from primary bovine
cells by immortalisation or complete transformation with El of BAV2, the rationale being that
primary cells transformed by the E1 oncogenes will result in a stable cell line as far as the
retention and expression of the El genes are concerned. Such cells will continue to grow in
culture as long as El expression is maintained since the transformed phenotype is dependent on
El expression (Graham et al., 1977). The type of packaging cell line we hoped to isolate by this
method was one capable of generating recombinants with missing El, with or without
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replacement by a foreign gene insert, and one able to support subsequent propagation of the
recombinant virus.
In order to establish the desired BAV2 packaging cell line, a transforming plasmid
containing BAV2 E I coding sequences with their appropriate transcriptional control elements
was constructed. Several considerations must be taken into account in the design of such a
plasmid. First, it must readily transform primary cells by virtue of EIA and EIB expression.
This required precise selection of BAV2 EI sequences to be included in the transforming
plasmid. Previous studies have demonstrated that BAV2 genetic organization is similar to those
of the widely studied human Ads and that both E1A and EIB regions have high percentage of
identity with those of human Ad EIA and EIB (Salmon and Raj-Ahmad, 1994 ; Ojkic, 1997).
By simple sequence alignment and comparison, delineating those sequences comprising the
complete EIA and EIB genes can be done with a high degree of accuracy. Second, the resulting
cell line must avoid one of the deficiencies associated with the 293 packaging cell line, which is
its propensity to produce wild-type revertants from EI-deletion/replacement mutants (reviewed
in Hitt et al., 1997). Studies have shown that revertants generated by 293 cells occurred by
genetic recombination between homologous sequences present in the viral genome and those in
293 cells (reviewed in Hitt et al., 1997). The mechanisms involved in homologous
recombination are well known, hence it was possible to incorporate features into the
transforming plasmid that prevents genetic recombination leading to wild-type revertants. These
features are elaborated in the next section.
A. Construction of a transforming plasmid containing SAV2 E1
The strategy for constructing a plasmid intended for immortalization and transformation
of primary cells with eventual use as packaging cells for BAV2 E I-deletion vectors is shown in
Figure 6. The basic design includes placing the complete BAV2 EI coding sequence under
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control by a cytomegalovirus (CMV) transcriptional element (enhancer/promoter). In this design,
the CMV promoter replaces the E 1A promoter and all sequences from leftward on. By doing
this, viral sequences at the extreme left end that can serve as an initiation site for homologous
crossover are replaced by foreign sequences consisting of the CMV control elements.
Elimination of crossovers near the left end effectively destroys chances for a double-crossover
that is required for generating wild-type revertants (Figure 7 and Figure 8).
The overall strategy for the construction of the transforming plasmid, pCMV-E1, as
shown in Figure 9, describes the series of cloning steps required to arrive at the desired plasmid.
The details of each cloning step and the methods used to verify the resulting intermediate
plasmids are described in the legends to the subsequent figures. Briefly, the first cloning step
involved pBB 12 , a plasmid containing the left 17.5% of the BAV2 genome (Salmon, 1993) as
the source of E 1A and E 1B coding sequences. This plasmid was modified by inserting a linker
into the 1.1 % position to convert the Eag! site into BamH! resulting in the plasmid pBB 12-B
(Figure 10). This step was necessary to allow fusion of the CMV promoter with the El
sequences (Figure 11) at the 1.1 % position that contained the converted BamHI site. The CMV
promoter was obtained from the plasmid pCMV53, which is a derivative of the commercially
supplied pCMVp. The plasmid pCMV53 (Figure 12 and Figure 13) contained a convenient
BgII! site at the 3'-end of the CMV promoter to serve as the site for fusing with the E 1
sequences. The resulting plasmid was called pCMV-E 1 (Figure II).
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Figure 6: Overall construction strategy for the plasmid pCMV-E1-neo
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Figure 7: Ad reversion to wild-type through homologous recombination in 293
cells.
Diagrammatic representation of homologous recombinations that result in the
emergence of replication competent Ad (RCA) during propagation of E1 deleted Ads in
293 cells.
A - Homologous recombination occurs between homologous sequences in the 293
chromosome and the viral genome.
B - RCA emergence as a result of a double cross over between the integrated
sequences and the E1-attenuated viral genome resulting in restoration of missing E1
sequences.
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Figure 8: Prevention of generation of Ad wild-type revertants.
Diagrammatic representation of cell line engineering to minimize reversions to wild-type.
A - E1A promoter was replaced with the CMV promoter in order to eliminate the
possibility of a homologous recombination at the left end of the genome.
B - Wild-type revertants are not generated since one cross over does not restore the
missing E1 coding sequences.
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II.
Enzymes
Fragment Sizes (bp)
BamHl
5,403
2,686
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3,724
III. 23,130+
9,416+ 111.••
6,557+
4,361+
2,322+
2,027+
Figure 10: Restriction analysis of pBB12-B.
PBB12-B was constructed by replacing the unique Eagl restriction site with a BamHI
restriction site using a DNA linker as shown in Figure 9. (I) Restriction endonuclease
map of the plasmid (II) Table of the expected DNA fragment sizes and (III) A picture of
an agarose gel electrophoresis. Lane 1 shows the A marker used to estimate the DNA
fragment sizes, lanes 2 , 3, 4, shows the plasmid pBB12-8 digested with BamHI, EcoRI,
and SaIl respectively.
I. EccJ.{ ] (2)
Hind III (4839) Hind III (3937)
Hind III (2167)
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II. Enzymes
Fragment Sizes (bp)
EcoRI
9,117
BamHI
5,547
3,294
198
78
Hindill
4,800
1,645
970
902
800
III. 23,130-"9,416-"
6,557-'
4,361-"
2,322-.
2,027-.
Figure 11: Restriction analysis of pCMV-E1.
The plasmid pCMV-E1 was constructed by cutting the plasmid pBB12-B with the
restriction enzyme BamHI and the resulting 5.4kb DNA fragment was inserted into the
restriction site Bglll in the plasmid pCMV-53. The resulting plasmid, pCMV-E1, carries
E1 region of BAV2 (1.1-17.5% ) under the control of the CMV promoter instead of the
BAV2 E1 promoter (Figure 9). (I) Restriction endonuclease map of the plasmid (II)
Table of the expected DNA fragment sizes and (III) A picture of an agarose gel
electrophoresis. Lane 1 shows the A marker used to estimate the DNA fragment
sizes, lanes 2 , 3, 4, shows the plasmid pCMV-E1 digested with EcoR/, BamH/ and
Hind/II respectively.
PM
EcoR I (2)
~__-=:--CMV promotor lenhancer
Notl (820) GGCC
Digest with NotI
Ligate and Transform
EcoRJ (2)
PMB1
CGG
76
Figure 12: Construction strategy of the plasmid pCVM-53.
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Figure 13: Restriction analysis of pCMV53.
This plasmid was constructed by cutting the plasmid pCMV~ with the restriction enzyme
Notl to release the laeZ gene and inserting a linker at that site which would introduce a
polylinker containing the restriction sites of Bgll', Xaml, Nhel and CiaI restriction
enzymes as shown in Figure 12. The orientation or the polylinker was confirmed as
shown in Figure 14. (I) Restriction endonuclease map of the plasmid (II) Table of the
expected DNA fragment sizes and (III) A picture of an agarose gel electrophoresis.
Lane 1 shows the A marker used to estimate the DNA fragment sizes, lanes 2 , 3, 4,
and 5 show the plasmid pCMV 53 digested with Bg"', BamHI, Hind/II and Xho/
respectively.
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Figure 14: Orientation of the linker in the plasmid pCMV-53.
Autoradiograph of an agarose gel used to identify the orientation of the linker in the
plasmid pCMV-53. Since the linker was a Notl insert, it could assume two orientations
in the plasmid. To determine the orientation, the following experiment was done: First,
the plasmid pCMV-53 was digested with the restriction enzyme 8glll, then used klenow
to fill the sticky ends in a reaction mixture that contained a-32p_dATP. Then the plasmid
was digested with Clal and EcoRI. The 820 bR framgment resulting from the digestion
with EcoRI and Clal would be labelled with 32p ATP only if the linker went in the
following direction: 8gll', Xmal, Nhel, Clal at 821, 827, 833, and 840 bp respectively on
the plasmid. Lane 1 shows a radioactive band with an approximate size of 2880bp, but
it does not show a radioactive band at 820bp which means that the orientation of the
linker is the following: CiaI, Nhel, Xma/, 8gll1 at 821, 827, 833, and 840 bp respectively
on the plasmid (referred to as the "minus" orientation). In Sample 2, another clone
shows two radioactive bands, one at 2880bp and the other at approximately 820bp.
The radioactive band at 820bp indicates that the linker was inserted in the opposite
direction to sample 1 (referred to as the "plus" orientation). The plasmid vector from
sample 2 (clone #16) was used in subsequent experiments.
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B. Transfection of Embryonic Kidney and Lung Cells
Transformation of primary cells obtained from organs of a bovine fetus was carried out to
explore the possibility of establishing cell lines that can serve as packaging cells for BAV2
recombinants, specifically those that are replication-deficient due to deletion of El functions. As
previously mentioned, this approach to establishing a bovine cell line is inherently advantageous
since such cells are only able to survive in cell culture if they acquired the immortalized
phenotype due to EtA effects alone, or the fully transformed phenotype due to cooperative
effects ofElA and EIB.
Thus, primary cells from bovine kidney and lung organs from an unborn fetus were
prepared as described in Materials and Methods. The source fetus was obtained from a local
slaughterhouse and appeared to be in its third trimester of gestation, judging from its size. Thus,
monolayer preparations of primary cells were transfected with the plasmid pCMV-E1 using the
calcium phosphate technique. Selection for outgrowers that form foci was based on the method
used in transformation assays as previously described (Graham et aI., 1977).
Transfected cells were observed carefully for signs of foci formation for several weeks in
pCMV-E1-transfected kidney or lung cell preparations and comparing them with mock-
transfected controls. Monolayers of primary cells first appeared as mixture of fibroblastic and
epithelial type. With or without pCMV-EI, the transfected cells continued to grow, requiring
passaging at times to prevent overcrowding in the plates. Over time, there was a gradual
appearance of predominantly fibroblastic cells and disappearance of those with epithelial
morphology. No foci were ever observed. Eventually, the fibroblastic cells became quiescent and
appeared to have stopped growing. At this stage, the cultures were discarded.
The attempt to establish immortalized cells from primary cultures of bovine kidney and
lung cells was unsuccessful and it may have been due to couple reasons. First, BAV2 E1 might
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have failed to transform primary bovine cells since BAV2 £1 might have an inherently poor
transforming activity hence it cannot readily immortalize primary cells. The second possibility is
that the bovine cells used for transfection might have already reached terminal differentiation,
adding to the difficulty in isolating de-differentiated, transformed phenotype. These possibilities
are further explored in the Discussion.
C. Biochemical Transformation of Established Bovine Cell Lines
In this effort to isolate a suitable packaging cell for BAV2, the focus was shifted to using
available established cell lines from which derivatives can be developed by transfection with
BAV2 El linked to a selectable marker. In this approach, transfected cells will be biochemically
transformed by virtue ofa neo selectable marker to be linked with pCMV-EI. The strategy was
to isolate cells that constitutively express E1 from the population of G418-resistant cells (neo+).
To link the neo gene with the El-containing plasmid, pCMV-El, the neo coding
sequence was obtained from a commercial plasmid, pUC4K (Clonetech™). Since the neo gene
in this plasmid did not contain a mammalian transcriptional control element, a derivative was
constructed so that the selectable marker was now under the control of the CMV promoter
(Figure 15). The cloning of this plasmid required an intermediate called pCMV-Eco (Figure 15
and Figure 16) that was used to obtain the plasmid pCMV-neo (Figure 17). The fmal step for
linking the neo gene with the El-containing plasmid involved the transfer of the neo-containing
fragment from pCMV-neo into pCMV-El, to produce the pCMV-El-neo (Figure 18 and Figure
19).
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Figure 15: Construction strategy of the plasmid pCMV-neo.
I. EcoR 1(2)
BamH 1(709)
V40 Splice Donor/Acceptor
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II. Enzymes
Fragment Sizes (bp)
CiaI
3,713
EcoRI
2,644
1,069
BamHI
3,293
198
144
78
III. 23,130 ...9,416 -.
6,557 ...
4,361~
2,322-.
2,027-.
Figure 16: Restriction analysis of pCMV 53-Eco.
This plasmid was constructed by cutting the plasmid pCMV-53 with the restriction
enzymes SaIl and Hindlll and ligating it to a linker that is compatible to the SaIl and
Hindlll sticky ends without restoring the restriction sites but instead it introduces a new
EcoRI restriction sequence at that site. (I) Restriction endonuclease map of the plasmid
(II) Table of the expected DNA fragment sizes and (III) A picture of an agarose gel
electrophoresis. Lane 1 shows the A marker used to estimate the DNA fragment
sizes, lanes 2 , 3, 4, shows the plasmid pCMV 53-Eco digested with Clal, EcoRI and
BamHI respectively.
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neo
BamH I (631)
Xho I (641)
BamH I (709)
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Xho I (989)
BamH I (2117)
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BamH I (2315)
EeoR I (2335)
pCMV-neo
4977 bp
CMV Promoter/enhancer
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4,629
348
II. Enzymes
Fragment Sizes (bp)
BamHI
4,977
EcoRI
3,293
1,408
198
78
XhoI
ID. 23,130 -.9,416~
6,557-'
4,361-'
2,322 ....
2,027 ....
Figure 17: Restriction analysis of pCMV-neo.
The neo gene was released from pUC4K using the restriction enzyme BamHI and
inserted into the Bglll site, which has compatible restriction sticky ends to the sticky
ends generated by the enzyme BamHI, in the plasmid pCMV-53-Eco. (I) Restriction
endonuclease map of the plasmid (II) Table of the expected DNA fragment sizes and
(III) A picture of an agarose gel electrophoresis. Lane 1 shows the A marker used to
estimate the DNA fragment sizes, lanes 2 , 3, 4, shows the plasmid pCMV-neo digested
with BamHI, EcoRI and Xhol respectively.
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Figure 18: Construction strategy of the plasmid pCMV-E1-neo.
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EcoRI
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2,333
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4,964
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9,416~
6,557~
4,361~
2,322~
2,027~
Figure 19: Restriction analysis of pCMV-E1-neo.
This plasmid was constructed by combining the plasmids pCMV-E1 and pCMV-neo.
The neo gene under the control of the CMV promoter was released from pCMV-neo
with the restriction enzyme EcoRI and cloned into the EcoRI site in pCMV-E1. (I)
Restriction endonuclease map of the plasmid (II) Table of the expected DNA fragment
sizes and (III) A picture of an agarose gel electrophoresis. Lane 1 shows the A marker
used to estimate the DNA fragment sizes, lanes 2 , 3,4, shows the plasmid pCMV-E1-
neo digested with EcoRI, BamHI and SaIl respectively.
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D. Transformation of MDBK Cells
MDBK cells were the first established cells to be transfected with pCMV-El-neo. To
obtain high efficiency of gene transfer, electroporation was used as described in Materials and
Methods. Briefly, the cells were allowed to recover for 24 hours in MEM media supplemented
with 10% FBS serum before selection with the drug 0418 was initiated. When foci were visible,
under light microscopy, cells were lifted by trysinization and plated at 1 cell/well to isolate single
clones. Independent foci were isolated to a total of 48 for further characterization. Each clonal
transformant was expanded for analysis ofE1 expression.
E. Analysis of G418-Resistant MDBK Cells
1. Northern Blot
Quantitative assessment for E1 expression in the 48 independent foci was carried out by
Northern blotting analysis. Figure 20 shows the result of probing for El-specific transcripts from
extracts of the 48 colonies. The result showed that 2 isolates, labeled L-23 and L-24
respectively, in a total of 48 expressed high levels of El transcripts. These cell lines were then
subjected to further investigations in order to study their DNA uptake efficiency.
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288 -.
188 -.
Figure 20: Northern blot analysis.
Total RNA was isolated from the cell lines, L-23 (lane 1), L-24 (lane 2), MDBK infected
with BAV2 (lane 3) and MDBK control RNA (lane 4). The RNA isolated was subjected
to agarose gel eclectrophoresis and then transferred to a nylon membrane. Positions
of 188 and 288 bands are indicated on the left end of the gel. The membrane was
probed with E1 of BAV2 (0 to O.6°~).
2. DNA uptake analysis
The efficiency of the MDBK-derived cells that express high levels of BAV2 £1 was
determined in a transient expression assay using the lacZ reporter gene in the plasmid pCMVp
using the calcium phosphate and lipofectamine methods for transfering DNA. These methods
revealed that both transformed cell lines L-23 and L-24 were, like the original cell line, MDBK,
very poor at transient DNA uptake and expression (Figure 21) compared to other cell lines, such
as Hela and 293. These results led to the idea of acquiring other established cell lines, testing
them for DNA uptake and then choosing the efficient cell lines at picking up DNA to be
transfected with pCMV-E1-neo.
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Figure 21: Transient DNA uptake and expression studies.
DNA uptake studies on MDBK, and transformants L-23 and L-24. Cell transfections,
with the plasmid pCMV~, was done in 6-well plates when cell confluency reached 50
percent. The cells were fixed and stained for laeZ activity 24 hours post-transfection.
Blue cells were counted in ten randomly selected fields per plate and numbers are
expressed as a percentage. Error bars show standard deviation value for three sets of
data from independent sets of experiments.
F. Characterisation of Other Bovine Cell Lines
The low efficiency in DNA uptake of the transformed cell lines, L-23 and L-24,
persuaded us to test other pre-established bovine cell lines. A total of nine cell lines (CCL-40,
CCL-44, CRL-1390, CRL-6017, CRL-6033, CRL-6043, CRL-6055, CRL-6061, CRL-6072)
were initially tested for permissivity to BAV2 and then for DNA uptake efficiency. The goal of
this study was to fmd a cell line that is permissive to BAV2 and is efficient at DNA uptake. The
cell line with these properties could then be used to be transfected with pCMV-EI-neo in order to
establish a packaging cell line.
1. Permissivity to BAV2
All cell lines were tested for permissivity to BAV2 viral infection. The cells were grown
to about 80 % confluency after which they were infected with BAV2 at 10 moi (multiplicity of
illrectioll) . li11es s110vved
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(cytopathic effect) fOUf to six days post infection. Dl"\TAA \vas
isolated ce I1s following cOlnplete Restriction anaiysis of tIle isolated DNi-\
revealed presellce BAV2 DNpl;.. Therefore, all cells \vere perlnissive to B.:\. infection.
22: 1 photograph of counter stained eel 40 ceils
p.~ - f\Jormal eel 40 celi morphology (40 x nlagnification)
B - Morphology of eel 40 cells eXhibiting cytopathic effect 48 hours post infection \J\Jith
B·A" J,-.. t· • O· f' f"·· ( .\ (40 ....... \i: \VL a~ 1 ) O. in ectlon mOli-.'- x magniTlcatiOnj
2. uptake efficiency
TIle nille otl1er bovine establis11ed bovine cell li11es were tl1en tested for reoorter DNA
- .... . .1.
uptake in a trar1siel1t expression assay. The plasl11id pCMV~ , 'Vvliich carries the bacterial [cfeZ
ge11e, \vas llsed again these studies. Follo\tv1Ilg transfection, the cells vvere stained \rvith X~gai
for ZacZ activity. Tl1e blue cells \tvere counted under light l11icroscopy and an average of 10 fields
per plate \vas calcll1ated a11d preser1ted with a standard deviation (Figure 23).
TIle restdts shovved t11at eeL 40 appeared tahave a transfection efficiency of about 30%,
com.pared to 600/0 for 293 cells used as a control. Al10t11er cell line, CRL 6055, s110\ved a
COl11parably 111gb efficiency_ i\ll otlier ceil seven cell lines vvere poor ill trallsfection (belovv 100/0)
(Figure 24).
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Figure 23: Transient DNA uptake efficiency and expression in various bovine ceil
lines.
Determination of transfection efficiency of various established bovine cell lines. Cell
transfections, with the plasmid pCMV0, in 6-well plates when cell confluency reached
50 percent. The cells were fixed and stained for /aeZ activity 24 hours post-
transfection. Blue cells were counted in ten randomly selected fields per plate and
numbers are expressed as a percentage. Error bars show standard deviation value for
three sets of data from independent sets of experiments.
Figure 24: Photographs of mammalian cells lines stained for lacZ activity.
Cells were stained following transfection with the plasmid pCMV0 which carries the
bacterial/aeZ gene under the control of the CMV promoter.
A - MDBK cells, arrows indicate blue cells (40 x magnification)
B - eel 40 cell line (40 x magnification)
C - 293 cells (40 x magnification)
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3. Transfection and Selection
Due to its high transfection efficiency, the cell line CCL-40 was chosen for its high DNA
uptake efficiency to be used in establishing a packaging cell line. The cells were transfected with
the plasmid vector pCMV-E1-neo. The transfection and selection procedures were done in the
same manner as in the case ofMDBK cell lines. However, in a titration experiment to determine
the level of sensitivity of these cells to the drug G418 revealed that CCL-40 cell line is more
sensitive than MDBK cell line. MDBK cells can tolerate a level up to 75 f.lg/ml ofG418 where
CCL-40 cells can tolerate a maximum concentration of 25 f.lg/ml of G418 before cell death
occurs. Therefore, a selection concentration of 50 f.lg/ml G418 was used.
Following selection, the resistant cells were expanded as a heterogeneous mixture without
subcloning into single foci. Two cell lines were grown separately, namely, Pro-cell 1 and Pro-
cell 2. These two cell lines were then subjected to northern blot analysis to determine the
presence ofE1 mRNA trasncripts, which would be an indication ofE1 expression.
4. Northern Blot
In order to determine the level of E1 expression, total RNA extracted from the cell lines
ProCell 1 and ProCell 2 was subjected agarose gel ecletrophoresis and followed by northern blot
analysis. Using an £1 probe (0 to 6% ofBAV2 genome) both cell lines revealed the presence of
BAV2 E1 region (Figure 25).
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Figure 25: Northern blot analysis.
Total RNA was isolated from the cell lines, ProCell 1 (lane 1), ProCell 2 (lane 2), CCl-
40 infected with BAV2 (lane 3) and CCl 40 control RNA (lane 4). The membrane was
probed with E1 of BAV2 (0 to 6°R> of the BAV2 genome).
G. Development of shuttle vectors for rescuing SAV2 recombinants With the
lacZ gene in place of E1 Region
In the following study, a plasmid vector carrying part of BAV2 DNA was used to insert
the lacZ gene into previously established deletions in E1 region of BAV2. The plasmid was co-
transfected with wild type viral DNA in order to allow for homologous recombination which
would result in a mutant virus carrying the lacZ gene in place ofE1 region.
In order to rescue a mutant using homologous recombination, the plasmid DNA and the
viral DNA have to have an area of overlap which in case of contact, a cross over would occur
resulting in a viral genome that carries the foreign gene. Therefore the plasmid DNA was
linearized with BgIII restriction enzyme and the viral genomic DNA was digested with BamHI
resulting in approximately 4 kbp of region of overlap (Figure 26). Both plasmid and genomic
DNA were co-transfected into L-23 and L-24 cell lines at different concentrations using the
calcium phosphate method. Although, viral mutants were not generated during co-transfection
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experiments, wild-type BAV2 virus was generated by transfecting cells with non-digested viral
DNA.
E1B 19 kd E313.7 kd
1.1%
Eag 1(364
E1A 32 kd(56Q-916 bp)
8.25%
BstBI (2729)
E1B 55 kd (1670-2860 bp)
___E1 Deletion (364-2729 bp)
1.1 - 8.25%
pVl11 (24094-24948 bp)
81.40/0
ca 1(26874)
FIBER(2697Q-28640 bp)
......-_E3 Deletion (25009-26874 bp)
75.8 - 81.4%
E3 Spontaneous Deletion
(24917-26217 bp)
75.4 - 79.30/0
Figure 26: A schematic representation of the BAV2 genome.
The genome (33034 bp) is divided by convention into percentile units going from
0% to 100ok. The E1 deletion was done using the restriction enzymes Eagl and BstBI
shown on the map at 1.1°k and 8.25°k respectively. The E3 deletion was made by
using the restriction enzymes Pstl and Seal shown at 75.8°k and 81.4°k respectively.
The spontaneous E3 deletion occurred, as indicated on the map, between 75.4°k and
79.3 Ok.
1. Construction of pdlE1 E-Z
The plasmid pdlElE-Z was constructed to be used as a tool in BAV2 mutant rescue
experiments. The lacZ gene was inserted in the forward orientation in this scheme. The cloning
strategy involved first the modification of the plasmid pCMV~ in order to introduce a unique
KpnI restriction site, resulting in the construction of the plasmid pCVM~-K (Figure 27). This
plasmid was confirmed by restriction enzyme analysis as shown in Figure 28. The expected
restriction DNA fragments were observed on the gel (Figure 28). The plasmid pCMV~-K was
then combined with the plasmid pdlEl-E to give the plasmid pdlEl-E-Z. The plasmid pdlEIE-Z
contains BAV 2 sequence from 0% to 40.4% with the El region deleted using the restriction
enzymes Eag! at 1.1% and BstBI at 8.25% (ElA and EIB regions extend from 1.7% to 2.8% and
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5.1 % to 8.66% respectively). The lacZ gene under the control of the CMV promoter was
inserted in the deletion in the forward direction.
Digest with
EcoRI
Ligate and Transfonn
0-/.
Digest with
KpnI and XhoI
S.1I1
Digest with
KpnI and Sail
Ligate and Transform
Amp 0·/. SAV2
Figure 27: Cloning strategy for pdIE1E-Z.
The commercially available plasmid, pCMVp, was modified using a linker to introduce a
new Kpnl restriction site instead of the unique EeoRI site. The resulting plasmid,
pCMVP-K was combined with the plasmid pdIE1-E, which carries up to 40.40/0 of the left
end of BAV2 genome. The final plasmid, pdIE1-E-Z contained the laeZ gene under the
control of the CMV promoter being expressed in the forward orientation.
I.
II.
Kpn 1(7)
CMV promotor/enhancer
BamH I (637)
BamH 1(715)
"
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Enzymes
Fragment Sizes (bp)
Kpnl BamHI
7,170 3,594
3,300
198
78
SaIl
7,170
III. 23,] 30"
9,416+
6,557-'
4,361-'
2,322+
2,027-.
Figure 28: Restriction analysis for pCMVp-K.
This plasmid was constructed by cutting the plasmid with the restriction enzyme EcoRI
and ligating in the presence of a linker that carries compatible sticky ends to the EcoRI
restriction site but carries the Kpnl recognition sequence. (I) Restriction endonuclease
map of the plasmid (II) Table of the expected DNA fragment sizes and (III) A picture of
an agarose gel electrophoresis. Lane 1 shows the A marker used to estimate the DNA
fragment sizes, lanes 2 , 3, 4, shows the plasmid pCMV~-K digested with Kpnl, BamHI
and SaIl respectively.
I.
II.
Amp
Enzymes
Fragment Sizes (bp)
ClaI
18,193
BAV2
BamH I (8347)
BamHI
7,578
3,691
3,594
3,054
198
78
CIa I (2573)
lacZ
BamH I (5095)
BamH I (5293)
XhoI
18,193
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III. 23,130 ..9,416+
6,557+
4,361+
2,322+
2,027-.
Figure 29: Restriction analysis of pdlE1 E-Z.
The plasmid pdlE1 E-Z was constructed by digesting the plasmid vector, pCMVp-K with
the restriction enzymes Kpnl and SaIl. The resulting fragment was cloned into the
Kpnl and Xhol restriction sites in the plasmid pdIE1-E. (I) Restriction endonuclease
map of the plasmid (II) Table of the expected DNA fragment sizes and (III) A picture of
an agarose gel electrophoresis. Lane 1 shows the Amarker used to estimate the DNA
fragment sizes, lanes 2 , 3, 4, shows the plasmid pCMVP-K digested with C/al, BamHI
and Xhol respectively.
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The use of the plasmid pdlE1E-Z in BAV2 mutant rescue experiments requires the use of
packaging cell lines that express the ElBAV2 region. Therefore, transfections were done using
the cell lines L-23, L24, ProCell 1 and ProCell 2. The plasmid DNA was co-transfected with
wild-type viral DNA at a one to one ratio using both lipofectamine® and calcium phosphate
method. However, these attempts did not result in the generation of a BAV2 mutant.
2. Construction of pdlE1 E-Z-R
In a study by Bramson and co-workers (1996), the expression of foreign DNA inserted in place
of deleted E3 region was influenced by the presence or the absence of intact E1 region in the
viral vector. When E1 region was kept intact, the foreing gene was only expressed in the
rightward orientation, however when the viral vector contained an E I-deletion, the foreign gene
was observed to be expressed when present in both orientation. Consequently, we decided to
insert the lacZ gene in both forward and reverse orientations, in case one of the orientations does
not result in active transcription of the gene.
The plasmid pdIEIE-Z-R therefore, contained the same E1 deletion as pdIEIE-Z,
however the laeZ gene was inserted in the reverse direction. This plasmid was also used to
attempt to rescue a BAV2 mutant with an E1 deletion. The laeZ gene was inserted in the
reverse direction in case the forward orientation had a negative influence on the expression of the
other viral genes resulting in a non-viable virus. Therefore, the reverse orientation should have
opposite or no effects in terms of modulating other viral gene expression that would inhibit viral
growth.
The cloning strategy involved the modification of the plasmid pCVM~ in order to
introduce a unique Sail site in place of the unique EcoRJ site (Figure 30). That resulted in the
construction of the plasmid pCMVp-S. The plasmid pCMVP-S was confirmed by restriction
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enzyme analysis and the expected fragments were observed on the agarose gel electrophoresis as
shown in Figure 31. The following step was to combine the plasmid pCMV~-S with the plasmid
pdlE1E resulting in the construction of the plasmid pdlE1E-Z-R, which was confinned by
restriction enzyme analysis, as shown in Figure 32. The expected DNA fragment size was
observed on the agarose gel electrophoresis.
San
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Ligate and Transform
Figure 30: Cloning strategy for pdlE1 E-Z-R.
The commercially available plasmid, pCMVp, was modified using a linker to introduce a
new Sail restriction site instead of the unique EeoRI site. The resulting plasmid,
pCMV~-S was combined with the plasmid pdIE1-E, which carries up to 40.4% of the left
end of BAV2 genome. The final plasmid, pdIE1-E-Z contained the laeZ gene under the
control of the CMV promoter in place of the E1 region and being expressed in the
reverse orientation.
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PMB1
Sal I (4526
Bam H I (45]4)
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Sal I (9)
CMV promotor/enhancer
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Fragment Sizes (bp)
XhoI
7,177
BamHI
3,594
3,307
]98
78
SaIl
4,517
2,660
III. 23,130~9,4]6~
6,557~
4,361~
2,322~
2,027~
Figure 31: Restriction analysis of pCMVp-S.
This plasmid was constructed by cutting the plasmid pCMVp with the enzyme EcoRI
and ligating in the presence of a linker that contains compatible sticky ends to the
EcoRI restriction site but carries the recognition sequence for the enzyme SaIl. (I)
Restriction endonuclease map of the plasmid (II) Table of the expected DNA fragment
sizes and (III) A picture of an agarose gel electrophoresis. Lane 1 shows the A marker
used to estimate the DNA fragment sizes, lanes 2 , 3, 4, shows the plasmid pCMVP-K
digested with BamHI, Hindlll and Xhol respectively.
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Ecd{ I (8995)
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Xho I (4667)
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EcoRI
11,316
6,884
BamHI
7,578
3,677
3,594
3,057
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78
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18,200
Figure 32: Restriction analysis of pdlE1 E-Z-R.
This plasmid was constructed by digesting the plasmid pCMV~-S with the restriction
enzyme Sail, the resulting fragment was ligated to the plasmid pdlE1 E-l-R after being
digested with the enzyme Xhol. (I) Restriction endonuclease map of the plasmid (II)
Table of the expected DNA fragment sizes and (III) A picture of an agarose gel
electrophoresis. Lane 1 shows the A marker used to estimate the DNA fragment
sizes, lanes 2 , 3, 4, shows the plasmid pdlE1 E-Z-R digested with EcoRI, BamHI and
Xhol respectively.
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The plasmid pdIE1E-Z-R was transfected into the E1 expression cell lines, namely L-23, L-24,
ProCell 1 and ProCell 2. The lipofectamine® and the calcium phosphate methods were used in
these transfections. However, that did not result in rescuing a BAV2 mutant.
3. Construction of pdIE3-5-Z
The plasmid pdIE3-5-Z contains BAV2 sequences from 64.8% to 100%. The E3 region
occurs on the BAV2 genome between protein VIII (72.9-75.5%) and the fibre protein (81.6% to
86.7%) at 75.7% to 81.36%. The £3 deletion was done using the restriction enzymes Pst] at
75.8% and Seal 81.4%. The insertion of the laeZ gene in place of the E3 region would allow for
rescuing a BAV2 viral mutant. The E3 deletion mutants do not require the E1 expression
packaging cell lines. Therefore, normal CCL40 and MDBK cell lines were used in these rescue
attempts.
The cloning strategy of the plasmid pdIE3-5-Z included a single cloning step on
combining the plasmid pd1E3-5 with the plasmid pCMVP-K as shown in Figure 33. The plasmid
was confirmed using restriction enzyme electrophoresis and the expected fragment sizes were
observed on the agarose gel electrophoresis (Figure 34).
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Figure 33: Cloning strategy for pdIE3-5-Z.
The plasmid pCMVP-K was combined with the plasmid pdIE3-5, which carries the right
end of BAV2 genome from 64.8% to 100%. The final plasmid, pdIE3-5-Z contained the
laeZ gene under the control of the CMV promoter in place of the E3 region and being
expressed in the reverse orientation.
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ORI
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EeaRl
13,377
3,593
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Figure 34: Restriction analysis of pdIE3-S-Z.
This plasmid was constructed by digesting the plasmid pCMVp-k with the restriction
enzymes Kpnl and SaIl. The resulting fragment was inserted in the Kpnl and Xhol
restriction sites in the plasmid pdIE3-5-Z. (I) Restriction endonuclease map of the
plasmid (II) Table of the expected DNA fragment sizes and (III) A picture of an agarose
gel electrophoresis. Lane 1 shows the A marker used to estimate the DNA fragment
sizes, lanes 2 , 3, 4, shows the plasmid pdIE3-5-Z digested with EcoRI, BamHI and
SaIl respectively.
The final construct, pdlE3-5-Z was co-transfected with wild type BAV2 viral DNA that
was previously digested with the restriction enzyme Xmal to eliminate the right end of the
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genome. Therefore allowing an overlap region of approximately 6.1 kb. These transfections
employed both the lipofectamine® and the calcium phosphate methods. However, these
transfections did not result in a BAV2 viral mutant.
H. Rescuing a SAV2 mutant with an E3 deletion
The full BAV2 genome was cloned into a cosmid vector, cosBAV2, and upon its
transfection into M5 cell line, it was shown to result in BAV2 viral particles (Ojkic, 1998). The
advantage of having the whole genome cloned into a cosmid vector is that it eliminates the
dependence on homologous recombination for the generation of viral vectors during viral mutant
rescue attempts. Therefore, the objective of this study was to modify the cosBAV2 by replacing
E3 viral genes with the neo gene and use the new construct to attempt to rescue a viral vector.
Consequently, cosBAV2 was modified through a series of cloning to suit our strategy (Figure
35). The final construct~ cosBAV2-neo , was then used to attempt to rescue a mutant by
transfecting the linearized cosmid vector into MDBK, M5 and CeL 40 cell lines.
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P(BLA)
I.Digest with KpnI
2.Treat with Kleno\\;
Ligate
and
Transform
Digest with EcoRI and Apal
Ape I (J"U)
Digest with EcoRl and Apal
X",,,,I(II}!lb
BAV2
BAV2
Apal (1712i)
Digest \\'ith ApaI and XmaI
Ligate and Transform
BAV2
Ligate and Transform
Digest \vith ApaI and XmaI
Digest with XmaI
neo
Ligate and Transform
AfXJl (17127)
Figure 35: Cloning strategy for cosBAV2-neo.
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1. Construction of cosBAV2-neo
The first step in constructing cosBAV2-neo was the elimination of a unique KpnI
restriction site from pdlE3-4Kan plasmid vector, which contained BAV2 sequence from 89.2%
to 100% with the neo gene cloned in place of deleted the E3 coding region (75.8 to 81.4%). That
resulted in the construction of the plasmid pdIE3-4-neo 1 which was confinned by restriction
enzyme digestions followed by gel electrophoresis analysis, shown in Figure 36. The plasmid
pdIE3-4-neol was combined with the plasmid cBAV-R to construct the plasmid cBAV-R-neo
which was confirmed as shown in Figure 37. Once the integrity of cBAV-R-neo was confirmed,
it was combined with cosBAV2 to construct cosBAV2-neo-A. This plasmid contained partial
sequence of the neo gene, therefore, kanamycin resistance selection was not applied during
screening for this plasmid. The cosmid construct, cosBAV2-neo-A, was confirmed through
restriction analysis as shown in Figure 38. In order to add the missing sequences of the neo gene,
cosBAV2-neo-A was combined with cBAV-R neo to construct cosBAV2-neo. This cosmid
vector contained the full BAV2 genome with a neo gene replacing the E3 region from 75.8 to
81.40/0. This final construct was confirmed through restriction analysis and gel electrophoresis as
shown in Figure 39.
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I.
BAV2
II. Enzymes
Sizes
BamHI Kpnl
20,626 No restriction
1,264 sites present
Sail
11,755
5,263
3,620
1.252
III. 23, 130"
9,416+ --
6.557+
4:361+
2,322..
2,027+
Figure 36: Restriction analysis of pdIE3-4-neo1.
This plasmid was constructed by cutting pdIE3-4-neo plasmid with the Kpnl restriction
enzyme followed by a treatment with the klenow enzyme to fill the sticky ends (Figure
35). The resulting plasmid pdIE3-4-Kan-1 was confirmed on agarose gel
electrophoresis (I) Restriction endonuclease map of the plasmid (II) Table of the
expected DNA fragment sizes and (III) A picture of an agarose gel electrophoresis.
Lane 1 shows the A marker used to estimate the DNA fragment sizes, lanes 2 , 3, 4,
shows the plasmid pdIE3-4-neo1 digested with BamHI, Kpnl and SaIl respectively.
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..BAV2
Sail (8259)
-.......
'. BatrHI(l1873)
Sail (11879)
BatrH I (1313?-};..->
Sail (13131) KN(R)
I.
AF}
pUC OR:;....'I~~......111110...-
BAV2
II. Enzymes EcoRI BamHI SaIl
Fragment Sizes (bp) 23,317 22,053
1,264
18,445
3,620
},252
III. 23,130 ..
9,416 -.
6,557 .....
4,361-'
2,322-'
2,027-+
Figure 37: Restriction map of.cBAVR-neo.
The plasmid pdlE3-4kan was digested with the restriction enzymes EcoRI and Apal.
The resulting fragment was inserted into the same restriction sites in the cosmid vector
cBAV-R resulting in the construction of the cosmid vector cBAV-Rneo (Figure 35). (I)
Restriction endonuclease map of the plasmid (II) Table of the expected DNA fragment
sizes and (III) A picture of an agarose gel electrophoresis. Lane 1 shows the A marker
used to estimate the DNA fragment sizes, lanes 2 , 3,4, shows the plasmid cBAVR-neo
digested with EcoRI, BamHI and Sail respectively.
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I.
AR
pUC ORI
Kpn I (2603 ) CO ~.t=-.~
BAV
ka. ~
Sail (2501
BanH 1(2501
Sail (2139
BanH I (5761)
Sail (9641)
II. Enzymes
Sizes
BamHI
19,249
10,774
Kpnl SaIl
26,029 11,755
3,994 8,602
6,046
3,620
III. 23,130 ....9,416-'
6,557 ....
4,361 ....
2,322 ....
2,027 ....
Figure 38: Restriction analysis of cBAV2-neo-A.
This plasmid was constructed by transferring the Apal to Xmal fragment from the
cosmid vector cBAV-Rneo the same restriction sites in cosBAV2 (Figure 35). (I)
Restriction endonuclease map of the plasmid (II) Table of the expected DNA fragment
sizes and (III) A picture of an agarose gel electrophoresis. Lane 1 shows the Amarker
used to estimate the DNA fragment sizes, lanes 2 , 3, 4, shows the plasmid cBAV2-
neo-A digested with BamHI, Kpnl and SaIl respectively.
I. APpUC ORI
cos
Kpn I (32461
Sail (21396)
Sail (9641)
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II. Enzymes
Sizes
BamHI
19,249
15.941
1,264
KpnI
32.460
3,994
SalI
11,755
11,225
8.602
3,620
1.252
III. 23,130-..•••••••9,416-+ _
6,557-'
4,361-+
2,322-.
2,027-.
Figure 39: Restriction analysis of cosBAV2-neo.
The cosBAV2-neo cosmid vector was constructed by combining cBAV-Rneo with
cosBAV2neo-A. CosBAVRneo was digested with the restriction enzyme Xmal and the
released fragment was inserted into the Xmal site in cosBAV2-neo-A to result in a
complete BAV2 clone that contains the neo gene in place of the E3 deleted region from
75.8 to 81.4% (Figure 35). (I) Restriction endonuclease map of the plasmid (II) Table of
the expected DNA fragment sizes and (III) A picture of an agarose gel electrophoresis.
Lane 1 shows the A marker used to estimate the DNA fragment sizes, lanes 2 , 3, 4,
shows the plasmid cosBAV2-neo digested with BamHI, Kpnl and Sail respectively.
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2. Transfection of cosBAV2-neo into bovine cell lines
The cosBAV2-neo clone was used to attempt to rescue a mutant by transfecting the
closed circular cosmid or the linearized fonn, by digesting it with the restriction enzyme Kpnl,
into MDBK, M5 and CCL40 cell lines. However, these transfections did not result in the
generation of a mutant virus. The possible reasons for are discussed further in the discussion
section.
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x. Discussion
Ad vectors are being rapidly developed for use in gene ther~gy and viral vaCCIne
technologies for applications in humans and other animals. Numerous human clinical protocols
using adenoviruses have already entered phase I clinical trials (Bilbao et aI., 1998). Although
there are over 40 serotypes of human Ads, only subgroup C serotypes 2 and 5 are predominantly
used as vectors. Other serotypes and Ads from non-human sources are also being examined for
their potential as vectors.
A property of Ad vectors is their ability to remain in episomal fonns in the nucleus of the
host cell and only rarely integrate within the cellular genome. Therefore, the use of Ad vectors
carries an advantage since the risk of integration and the consequent hazard of insertional
mutagenesis are minimized or even eliminated. However, this property of Ads also carries a
disadvantage in gene therapy, since expression of foreign DNA tends to be only transient (Verma
and Somia, 1997).
The wild-type Ad genome is 30 kbp to 44 kbp. The so-called "First generation" Ad
vectors, with deleted Eland E3 regions, can accommodate an insert of up to 8 kbp of foreign
DNA (Levrero et af., 1991). Although these viruses are attenuated and require a packaging cell
line to support viral DNA replication in vitro, viral proteins are still expressed at very low level
in vivo, and activate the immune system (reviewed in Hitts et al., 1996). To improve First
generation vectors, Ad vectors were further attenuated by including more deletions to produce
the so-called "Second generation" Ad vectors. The Second generation vectors include the so-
called "gutless" vectors which contain only the ITRs and a packaging sequence around the
transgene (Fisher et al., 1996). Such vectors, allow for large insert size of foreign DNA but
require helper virus for propagation. The development of vectors containing only few genes, as in
the "gutless" vectors, has resulted in prolonged in vivo transgene expression in liver tissue
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(Schieder et al., 1998) and in the muscle (Chen et aI., 1997), therefore, improving the rate of
success of transgene delivery through the use of Ad vectors.
Highly purified, attenuated Ad vectors are required for in vivo expressIon studies.
However, since these are almost invariably grown in 293 cells, they are likely non-homogenous.
Several methods have been developed to detect wild-type Ad contaminants, which arise during
virus growth in the 293 cell line. In a study by Wei and co-workers (1995), one plaque-forming
unit (Pfu) of wild-type virus can be detected, using a PCR-based method, in 109 pfu of
recombinant viruses. Therefore, this highly sensitive detection system enhances quality control
in the production of adenoviral vectors that are free of wild-type virus and suitable for gene
therapy applications. Another area of advancement in Ad vectors is in the preparation and
storage of stock virus. In a recent study by Croyle and co-workers (1998), a highly efficient
purification process for recombinant adenoviral vectors was developed. This protocol, based on
the cesium chloride purification method that require as long as 45 hours (Green and Pina, 1963),
employs the use of sucrose concentration gradient instead of cesium chloride, therefore
eliminating desalting step and consequently decreasing total preparation time by 15 hours. The
san1e study showed enhanced storage half-life of viral stocks by using lyophilized preparations
instead of the traditional glycerol storage method. A lyophilized viral stock of 1.4 x 1012 pfu/rnl
was reduced to only 0.6 x 1012 pfu/ml following storage at -20°C for 150 days compared to a
half-life of 34 days when using the traditional glycerol storage method.
The development of E I-deleted BAVs was patterned after the first generation Ad5
vectors. Thus, a bovine cell line, equivalent to the 293 packaging cell line had to be constructed.
However, problems associated with the 293 cell line and first generation Ad vectors were
addressed in our design of an ideal packaging cell line. This cell line must possess several
features to allow for efficient generation of recombinant viral vectors. First, the cell line must be
able to complement the El gene products that are missing from the viral vector, due to deletions
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introduced to accommodate foreign inserts. The E1 gene products are the first proteins expressed
after viral infection of a host cell and their major role is trans-activation of the other viral early
and late promoters. Because Ads missing EI region are replication-defective, the EI products
must be provided in trans in order for the E I-deleted BAVs to package as infectious virions. To
meet that criterion we constructed the plasmid pCMV-EI, which contained BAV2 EI region and
used it to transfect primary embryonic cells in attempts to isolate transformed cell lines.
The second feature is that the cell line must not support wild-type reversion of mutant
vectors through homologous recombination between the viral genomic DNA and the integrated
viral DNA in the cellular genome. This has been shown to be a common problem with the
human cell line 293. Even though the frequency of reversion is quite low, estimated at one in 105
to 106, one wild-type viral particle can give rise to 103 to 104 viral progenies upon infection of a
host cell and can outgrow the mutants by exponential growth (reviewed in Smith, 1995). That
type of viral stock cannot be used in gene therapy in vivo due to wild-type virus pathogenicity.
In the present study, we specifically addressed the problem of wild-type revertants by
constructing the plasmid pCMV-E1 in such a way that the CMV promoter replaces the E1
promoter. Replacing the promoter would eliminate the possibility of a crossover on the left end
of the genome and consequently eliminate the unintentional generation of wild-type BAVs.
The third feature of an ideal packaging cell line is that they must be easy to transfect to
recover virus from DNA. The difference in DNA transgene expression among cell lines lies in
their ability to transport the DNA through the cell membrane and transfer it to the nucleus
without degrading it (Orrantia and Chang, 1990). In a typical transfection experiment, the DNA
is complexed with either calcium phosphate precipitate (Graham and Van der Eb, 1973) or with
cationic lipids (FeIgner et a/., 1987). In both methods of transfection endocytosis is the main
type of DNA uptake (Zabner et a/., 1995). The DNA is then transported in endosomes that,
depending on the cell line, mayor may not fuse with lysozymes, which are known to be involved
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in DNA degradation of foreign DNA. The basis behind the DNA escaping degradation by
lysozymes is still not understood (Zabner et al., 1995). However, this escape of the DNA has
been mainly attributed to the difference between an efficient cell line and an inefficient cell line
in transient DNA expression (Jordan et aI., 1996).
The constructed plasmid vector pCMV-E1 was then used to attempt to immortalize cells
from primary cultures of bovine embryonic kidney and lung tissues. This attempt was
unsuccessful due to several reasons. First, BAV2 E1 might have failed to transform primary
bovine cells since both the virus and the cells belong to the same animal species. This seems to
be the general rule for Ads as experimentally observed for human, mouse and monkey Ads. In
other words, since bovine cells are permissive to BAV2, one should expect low levels of, or
perhaps zero, transformation frequency of such cells by BAV2 E1. It should be noted here,
however, that 293 cells were isolated as transformants of human embryonic kidney cells by
human Ad5 E1 (Graham el al., 1977), indicating that such transformation events, albeit rare, do
happen. Second, to date BAV2 has not been shown to transform cells, of the BAVs, only BAV3
has been shown to transform cells (Lukash et al., 1981 ),. The third possibility is that the bovine
kidney and lung cells used for transfection might have already reached terminal differentiation,
adding to the difficulty in isolating de-differentiated, transformed phenotype.
The inability of BAV2 E1 to immortalize primary cells in vitro urged us to attempt to
construct a BAV2 packaging cell line from pre-established bovine cell lines such as MDBK.
However, because these cells have been in culture for many generations, they will not depend on
E1 expression for growth and since no selective pressure can be applied to retain E1 genes, any
transfected E1 genes would be lost. The absence of E1 expression could also occur as a result of
nucleotide methylation, which was previously observed when Ad DNA integrates in host-cell
genome (reviewed in Doerfler, 1991). In order to assure the constitutive expression of the E1
region, the EI genes were expressed under the control of the CMV immediate early promoter. In
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addition, linking the £1 genes to a selectable marker would provide a means of selecting for cells
that contain the plasmid contruct carrying the £1 genes. Therefore, the plasmid pCMV-E1 was
modified further to carry the neo gene, which provide resistance to the drug 0418, and
accordingly named pCMV-El-neo. Through selection with G418, the transfected cells were
expected to express the drug resistance gene. Because the neo resistance gene and the E1 region
of BAV2 were linked in the same plasmid construct, it would be safe to assume that G418
resistant cells also express the E1 genes.
We tested the idea that El expression might improve DNA uptake of a cell line. This
hypothesis was based on the fact that 293 cells are very efficient in DNA uptake and
constitutively epxress Ad5 E1 genes. The cell line MDBK, which is very inefficient at DNA
uptake, was transfected with the plasmid pCMV-El-neo. Through selection with the drug G418,
48 foci were isolated, out of which two cell lines, L-23 and L-24, were found to express the E1
region of BAV2. Subsequent testing of L-23 and L-24 cells showed that only 0.34% of the cells
can take up trasnfected DNA, which was not different from parental MDBK cells, but far lower
than what is customarily seen in 293 cells in which trasnfection rates reach about 67% of the
cells. Therefore, these MDBK-based cell lines were not considered useful as a packaging cell line
and a search for a new cell line was initiated.
For the purpose of establishing a BAV packaging cell line, several bovine cell lines were
acquired and tested for transient expression of transfected DNA. The cell line CCL40 revealed
efficiency of expressing transfected DNA comparable to 293 cells. As in the case of MDBK,
these cells have also been grown in culture for several generations and will not depend on E1
expression. Consequently, the CCL40 cell line was transfected with pCMV-E1-neo, and
underwent selection with the drug G418 resulting in two cell lines, namely ProCell 1 and ProCell
2. It \\Tas assumed that G418-resistant cells would have the resistance gene integrated in its
genome as shown in many previous studies. In addition, it is assumed that G418-resistant cells
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also contained the E1 BAV2 genes, since the trasnfection vector, pCMV-E1-neo was constructed
in such a way as to link both genes under the control of separate promoters.
The cell lines ProCell 1 and ProCell 2 were not colony-purified; consequently, the site of
integration was not detennined. However, the result of a Southern blot analysis revealed that
these two cell lines, generated from independent experiments, were a mixture of different cell
lines (data not shown).
Expression of G418-resistance in the absence of E1 expression is possible in ProCell 1
and ProCell 2. This could be caused by partial insertion or DNA methylation in the regulatory
sequences which has been previously observed in integrated foreign DNA (Doerfler, 1991).
However, this study has shown high level expression of E1 as detected by a Northern blot
analysis. The long tenn stability of E1 expression, however, remains to be determined.
Overlapping DNA sequences between the viral DNA that is used to establish the cell line
and the DNA of the attenuated vector allow for double crossovers and the consequent generation
of wild-type revertants. Therefore, it is necessary to have non-overlapping regions. That can be
accomplished by designing the plasmid that is used to establish the cell line to have only those
viral DNA sequences that were deleted from the plasmid used to rescue the attenuated virus. In
our study, the plasmid pCMV-E I-neo carries BAV2 sequences from 1.1 % to 17.50/0. However,
the plasmid vectors used in attempts to rescue E I-deleted viruses carried a deletion between
1.1 % to 8.25%. Thus, these constructs do not allow for double crossovers and consequently
eliminate the possibility of generating wild-type viruses.
Attempts to rescue a BAV2 viral vector carrying the lacZ gene in place of E1 did not
result in the generation of a virus. These experiments were carried out using the constructed cells
lines, ProCell I and ProCell 2. The failure to generate a virus from these transfections could be
attributed to several reasons. First, this could have been caused by the failure to induce
homologous recombination between two different DNA molecules to generate a single DNA
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molecule which would get transcribed and translated to generate an infectious viral particle
carrying the lacZ gene. Meanwhile, transfection experiments done with non-digested viral DNA
did generate infectious wild-type viral particles. Second, the failure to recover a virus could have
been an indication of lack of complementation of E1 products in the ProCell 1 and ProCell 2.
However, the generation of defective E1 was unlikely since the expression cassette was
constructed to carry wild-type El region with only the promoter deleted. Third, the deletions
were based on examining the DNA sequence (Salmon and Haj-Ahmad't 1994; Esford and Haj-
Ahmad, 1994) for open reading frames and comparisons to other known Ad polypeptides to
determine the DNA sequences to be removed from E1 and E3 without removing any parts of the
adjacent genes. However, there was the possibility that some genes, which may be necessary for
the replication of the virus, \\'ere deleted, resulting in a non-viable virus.
Since virus rescue experiments using homologous recombination did not generate a virus,
a different strategy was used to eliminate the need for homologous recombination. That strategy
involved the modification of the vector cos-BAV2~ ~'hich was previously constructed in our lab
and carries the whole BAV2 genome. A cosmid vector, cosBAV2-neo \vas constructed, which
carries the neo gene in the "original" E3 deletion between 75.8% to 81.4% viral map units.
Attempts to rescue a mutant using this vector into CCL40 or CRL 6055 cell lines also failed. The
cell lines CCL40 and CRL 6055 cell lines were assessed in the lab and they demonstrated DNA
uptake efficiency of 37.5% and 28% respectively. Therefore, the DNA uptake efficiency of the
cell lines could not be the cause of deficiency in virus generation. However, the E3 deletion
made in this construct was the same size as the deletion in the plasmid pdIE3-5-Z plasmid.
Therefore, the fact that both constructs did not generate a viable mutant virus could be attributed
to the one property that is in common to both of these constructs, which is the size of the E3
deletion. Again, in this case, the DNA sequence was analyzed for open reading frames and
homology to other Ad vectors. The "original" deletion showed an accurate removal of the E3
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region without any parts of the adjacent genes. However, the same sequence analysis revealed
that the E3 spontaneous deletion, accidentally identified in our virus stock, ranging from 24917
bp to 26417bp (Ojkic, 1998) has actually removed 29 bp from the right end of the 854 bp coding
region of the neighboring protein eight (pVIII). This protein is associated with the outer capsid
and such deletions would have been considered to be lethal to the virus, since altering the
proteins associated with the outer capsid can alter the stability of the viral capsid as well as the
attachment and the internalization stages of the virus life cycle.
Since, the E3 spontaneous deletion is a viable deletion, it would have been a better option
to use in attempts to rescue viral recombinants instead of the "originar' deletion. Attempts to use
such a deletion would be more likely to generate a mutant virus. The strategy to construct such a
vector is outlined in the Appendix, showing the plasmids constructed and the final plasmid
needed to complete this strategy.
Future studies to evaluate and colony purify the cell lines ProCell 1 and ProCell 2 are
necessary for the development of BAV2 as viral vectors. The site of integration and the integrity
of the E1 sequences are to be determined in order to make predictions in terms of E1
complementation and the function of these cells as packaging cell lines. Also, the completion of
the construction of cos-BAV2-E3-P, which contains the laeZ gene in place of the spontaneous
deletion, would be needed for attempts to rescue an E3-deleted BAV2 virus. This rescue attempt
seems to be more promising since it carries the spontaneous deletion present in the virus stock
used in our lab.
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XI. Summary
Based on the results obtained in this study, the following conclusions can be stated:
I) The plasmids pCMV-E1, which contain E1 region of BAV2 from 1.1 % to 17.5%, and
the plasmid pCMV-E1-neo, which contains the El region linked to the neo gene,
were constructed.
2) Two cell lines, L-23 and L-24, based on MDBK cells, were constructed and shown to
express El region of BAV2. However, these cell lines suffer low efficiency in DNA
uptake.
3) Two cell lines, ProCell 1 and ProCell 2, based on CeL 40 cells, were also constructed
and shown to express E 1 region of BAV2. These cells were not colony purified, and
they show efficiencies of expressing transfected DNA of about 34%.
4) The plasmids pdIEIE-Z and pdIEIE-Z-R, which carry the lacZ gene in place of the
E 1 region were constructed.
5) The plasmid pdIE3-5-Z, \vhich carry the lacZ gene in place of the E3 region was
constructed.
6) The BAV2 genomice clone, cosBAV2-neo, which carries the neo gene in place of the
E3 region was constructed.
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XIII. Appendix
A. Development ofan E3 deletion SAV2 Genomic clone
1. Construction of cosBAV2-E3-Ascl
The purpose of this study was to clone the spontaneous deletion, which is present in the
viral stock currently used in our lab, with a uinque AscI restriction site at the exact position of the
deletion in a cosmid vector that contains the whole BAV2 genome (Figure 40). Such vector can
be used in attempts to rescue a mutant BAV2 virus that carries a foreign gene in place of deleted
E3 region. The cloning strategy is very close to completion. All the plasmids were cloned up the
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Figure 40: Construction strategy for cosBAV2-E3-B
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Figure 41: Restriction analysis ofpUCI9-AscI.
(I) Restriction endonuclease map of the plasmid (II) Table of the expected DNA fragment sizes
and (III) A picture of an agarose gel electrophoresis. Lane 1 shows the A marker used to
estimate the DNA fragment sizes, lanes 2 , 3, 4, shows the plasmid pdIE3-5-Z digested with
Aatll, Aatll + AscI and EcoRI respectively.
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Figure 42: Restriction analysis of pUC19-Ascl-L •
(I) Restriction endonuclease map of the plasmid (II) Table of the expected DNA fragment sizes
and (III) A picture of an agarose gel electrophoresis. Lane 1 shows the A marker used to
estimate the DNA fragment sizes, lanes 2 , 3,4, shows the plasmid pUC19-AscI-L digested with
ApaLI, AscI and HindII] respectively.
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Figure 43: Restriction analysis ofpUC19-AscI-R.•
(I) Restriction endonuclease map of the plasmid (II) Table of the expected DNA fragment sizes
and (III) A picture of an agarose gel electrophoresis. Lane 1 shows the A marker used to
estimate the DNA fragment sizes, lanes 2 ,3,4, shows the plasmid pUC 19-AscI-R digested with
ApaLI, EcoRI and AscI respectively.
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Figure 44: Restriction analysis of pUC19-E3-AscI.
(I) Restriction endonuclease map of the plasmid (II) Table of the expected DNA fragment sizes
and (III) A picture of an agarose gel electrophoresis. Lane 1 shows the A marker used to
estimate the DNA fragment sizes, lanes 2 , 3, 4, shows the plasmid pUC19-E3-AscI digested with
AscI, HindIII and EcoRI respectively.
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Figure 45: Restriction analysis of pUC19-E3-B-Rev.
(I) Restriction endonuclease map of the plasmid (II) Table of the expected DNA fragment sizes
and (III) A picture of an agarose gel electrophoresis. Lane 1 shows the A marker used to
estimate the DNA fragment sizes, lanes 2 , 3, 4, shows the plasmid digested with AscI, BamHI,
EcoRI and XhoI respectively
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B. Development of an E1 deletion SAV2 Genomic clone
1. Cloning Strategy of cosBAV2-E1-Z
The purpose of this study was to construct a cosmid vector that carries the laeZ gene in
place of deleted E1 region. This vector's construction is based on the construction of the vector
cosBAV2, which contains the whole BAV2 genome and was previously cloned in our lab. The
final construct cosBAV2-EI-Z would be used in attempts to rescue a BAV2 viral vector carrying
the laeZ gene in place of the E1 coding region. This mutant virus requires the packaging cell
lines ProCell 1 or ProCell 2, which would provide the E1 products to support viral growth.
Such construct would eliminate the dependence on homologous recombination to generate a
modified genomic DNA. Thus, making the rescue attempt experiments relatively easy where
only one type of DNA has to be transfected. All of the plasmids, up to the plasmid cosBAV-CD,
were constructed. Therefore, this experiment is only two steps away from completion.
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Figure 46: Construction strategy for cosBAV2-El-Z
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I.
i
If
PMB11
- ~.
.~,
SoIl (4522) __ y
BamH 1(4510) ,/,
BamH 1(4312)
Asc I (5)
pCMVB-Ascl-A
7173 bp
CMV promotor/enhancer
~-.~~a::H I (640)
~'" BamH I (718)
LACZ
II. E nzym es
Fragm ent Sizes (bp)
A sc I
7 ,173
Bam H I
3,594
3.303
198
78
SaIl
7 ,173
III. 23,130 ..
9,416 ....
6,557-+
4,361-'
Figure 47: Restriction analysis of pCMV~-AscI":'A
(I) Restriction endonuclease map of the plasmid (II) Table of the expected DNA fragment sizes
and (III) A picture of an agarose gel electrophoresis. Lane 1 shows the A marker used to
estimate the DNA fragment sizes, lanes 2 , 3, 4, shows the plasmid digested with AscI, BamHI
and Sail respectively
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II. Enzymes
Fragm ent Sizes (bp)
A scI
7 .1 7 3
Bam H I
3,594
3,303
198
78
EcoRI
7 ,173
III. 23,130 -.
9,416-'
6,557-'
4,361-'
Figure 48: Restriction analysis of pCMVP-Ascl-B
(I) Restriction endonuclease map of the plasmid (II) Table of the expected DNA fragment sizes
and (III) A picture of an agarose gel electrophoresis. Lane 1 shows the A marker used to
estimate the DNA fragment sizes, lanes 2 , 3, 4, shows the plasmid digested with AscI, BamHI
and EcoRI respectively.
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Hind III (45~_7l­
Asc 1(4523)
BamH I (4509)
Asc 1(4)
BamH 1(4311)
CMV promotor/enhancer
LACZ
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II.
Enzymes A scI BamH I HindIl X hoI
Sizes(bp) 4_5 19 3,594 7,180 7,180
2_661 3 _3 10
198
78
III. 23,130-'
9,416-'
6,557-'
4,361-'
2,322-.
2,027-.
Figure 49: Restriction analysis of pCMVP-AscI
(I) Restriction endonuclease map of the plasmid (II) Table of the expected DNA fragment sizes
and (III) A picture of an agarose gel electrophoresis. Lane 1 shows the A marker used to
estimate the DNA fragment sizes, lanes 2 , 3, 4, and 5 show the plasmid digested with AscI,
BamHI, HindIII and XhoI respectively.
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I.
APr- ...
ORI
Asc I (783)
Hind III (1554)
Hind III (2456)
II.
III.
Enzymes
Fragm ent Sizes (bp)
23,130~
9,416~:====~~=
6,557...
4,361
2,322-.
2,027 ....
AscI
6,109
EcoRI
6,109
HindIII
3,792
1,415
902
Figure 50: Restriction analysis of pBBdlEl
(1) Restriction endonuclease map of the plasmid (II) Table of the expected DNA fragment sizes
and (III) A picture of an agarose gel electrophoresis. Lane 1 shows the A. marker used to
estimate the DNA fragmentsizes, lanes 2 , 3,4, show the plasmid digested with AscI, BamHI and
HindIII respectively.
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I.
BamH I (8360
BAV2
Asc I (5302) BamH I (5090)
BamH I (5288)
------CMVIacZ
II. Enzymes A scI Bam H I EcoRI X hoI
Sizes (bp) 6 ~ 109
4 ~5 I 9
3.686 10,628
3,594
3,072
198
78
III. 23,] 30 ...
9,4]6 ....
6,557 ....
4,361 ....
2,322 ...
2,027-.
Figure 51: Restriction analysis of pBBdIEI-B
(1) Restriction endonuclease map of the plasmid (II) Table of the expected DNA fragment sizes
and (III) A picture of an agarose gel electrophoresis. Lane 1 shows the A marker used to
estimate the DNA fragment sizes, lanes 2 , 3, 4, and 5 show the plasmid digested with AscI,
BamHI, EcoRI and XhoI respectively.
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II.
Eag I (17425)
Enzymes
Fragment Sizes (bp)
BamHI
25,261
Sail
16,659
8,602
BamH I (5761)
EagI
8,200
8,164
5,059
3,057
781
III. 23,130 ....
9,416 ....
6,557 ....
4,361+
2,322+
2,027..
Figure 52: Restriction analysis of cosBAV-CD
(I) Restriction endonuclease map of the plasmid (II) Table of the expected DNA fragment sizes
and (III) A picture of an agarose gel electrophoresis. Lane I shows the A marker used to
estimate the DNA fragment sizes, lanes 2 , 3, 4, shows the plasmid digested with BamHl, Sail
and EagI respectively.
